<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article article-type="review-article" dtd-version="1.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ADMET</journal-id>
<journal-title-group>
<journal-title>ADMET &#x0026; DMPK</journal-title>
<abbrev-journal-title>ADMET &#x0026; DMPK</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1848-7718</issn>
<publisher>
<publisher-name>International Association of Physical Chemists</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.5599/admet.1883</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Infections associated with SARS-CoV-2 exploited via nanoformulated photodynamic therapy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Pallavi</surname><given-names>Pragya</given-names></name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Harini</surname><given-names>Karthick</given-names></name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Elboughdiri</surname><given-names>Noureddine</given-names></name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gowtham</surname><given-names>Pemula</given-names></name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Girigoswami</surname><given-names>Koyeli</given-names></name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Girigoswami</surname><given-names>Agnishwar</given-names></name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor1"><sup>*</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label>Medical Bionanotechnology, Faculty of Allied Health Sciences, <institution>Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE)</institution>, <addr-line>Kelambakkam, Chennai, TN-603103, India</addr-line></aff>
<aff id="aff002"><label>2</label><institution>Chemical Engineering Department, College of Engineering, University of Ha'il</institution>, <addr-line>P.O. Box 2440, Ha'il 81441, Saudi Arabia</addr-line></aff>
<aff id="aff003"><label>3</label>Chemical Engineering Process Department, National School of Engineers Gabes, <institution>University of Gabes</institution>, <addr-line>Gabes 6029, Tunisia</addr-line></aff>
<author-notes>
<corresp id="cor1">*Corresponding Author: E-mail: <italic><email>agnishwarg@gmail.com</email></italic>; Tel.: <phone>+91-9445 268 615</phone></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>07</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>11</volume>
<issue>4</issue>
<fpage>513</fpage>
<lpage>531</lpage>
<history>
<date date-type="received">
<day>08</day>
<month>05</month>
<year>2023</year>
</date>
<date date-type="rev-recd">
<day>30</day>
<month>06</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2023 by the authors.</copyright-statement>
<copyright-year>2023</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background and purpose</title>
<p>The pandemic of COVID-19 has highlighted the need for managing infectious diseases, which spreads by airborne transmission leading to serious health, social, and economic issues. SARS-CoV-2 is an enveloped virus with a 60&#x2013;140 nm diameter and particle-like features, which majorly accounts for this disease. Expanding diagnostic capabilities, developing safe vaccinations with long-lasting immunity, and formulating effective medications are the strategies to be investigated.</p>
</sec>
<sec>
<title>Experimental approach</title>
<p>For the literature search, electronic databases such as Scopus, Google Scholar, MEDLINE, Embase, PubMed, and Web of Science were used as the source. Search terms like 'Nano-mediated PDT,' 'PDT for SARS-CoV-2', and 'Nanotechnology in treatment for SARS-CoV-2' were used. Out of 275 initially selected articles, 198 were chosen after the abstract screening. During the full-text screening, 80 papers were excluded, and 18 were eliminated during data extraction. Preference was given to articles published from 2018 onwards, but a few older references were cited for their valuable information.</p>
</sec>
<sec>
<title>Key results</title>
<p>Synthetic nanoparticles (NPs) have a close structural resemblance to viruses and interact greatly with their proteins due to their similarities in the configurations. NPs had previously been reported to be effective against a variety of viruses. In this way, with nanoparticles, photodynamic therapy (PDT) can be a viable alternative to antibiotics in fighting against microbial infections. The protocol of PDT includes the activation of photosensitizers using specific light to destroy microorganisms in the presence of oxygen, treating several respiratory diseases.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>The use of PDT in treating COVID-19 requires intensive investigations, which has been reviewed in this manuscript, including a computational approach to formulating effective photosensitizers.</p>
</sec>
</abstract>
<kwd-group>
<title>Keywords</title>
<kwd>PDT</kwd>
<kwd>COVID-19</kwd>
<kwd>photosensitizers</kwd>
<kwd>vaccines</kwd>
<kwd>drug delivery</kwd>
</kwd-group>
<counts>
<fig-count count="3"/>
<table-count count="4"/>
<equation-count count="0"/>
<ref-count count="100"/>
<page-count count="19"/>
</counts>
</article-meta>
</front>
<body>
<sec id="sec1-1">
<title>Introduction</title>
<p>SARS is an airborne viral infection that spreads through mild droplets of saliva, much like the influenza virus and the common cold [<xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref>]. The outbreak of COVID-19 (Coronavirus disease-2019) has transformed into a global pandemic [<xref ref-type="bibr" rid="ref3">3</xref>]. The name of the virus causing COVID-19 is given by The International Committee on Taxonomy of Viruses (ICTV) [<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref5">5</xref>]. This became the first novel virus to emerge in the twenty-first century as both a severe and easily transmissible infection. The SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) virus is a single-stranded RNA virus that contains 29,903 nucleotides with a positive sense [<xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref7">7</xref>]. The transmission of these viruses was within animals until the end of 2019. As the seafood market in Wuhan (China), known for selling live animals like frogs, bats, birds, and snakes, has sold a virally infected organism, the infection of COVID-19 was transmitted to humans [<xref ref-type="bibr" rid="ref8">8</xref>]. Several terrible disasters occurred throughout this phase. China's National Health Commission has provided information about the pandemic, which has been linked to viral pneumonia. Eventually, a new coronavirus (SARS-CoV- 2) was discovered following on study based on affected individuals and genetic sequence research. Furthermore, with the discovery of genetic similarities between a new coronavirus and SARS-like bat viruses, researchers hypothesized that bats might be the sole reservoirs [<xref ref-type="bibr" rid="ref9 ref10 ref11">9-11</xref>].</p>
<p>In order to design preventive tactics to fight an infection, the origin and transmission channels must be recognized. The majorities of infected people who are identified with COVID-19 begin the viral process three days before the beginning of the symptoms and can last up to a week after the onset of symptoms. Incubation time varies from 2-14 days in individuals who become symptomatic [<xref ref-type="bibr" rid="ref12">12</xref>]. The overall symptoms, means of communication, diagnosis, and therapy, including prevention, are represented in <xref ref-type="fig" rid="fig001">Figure 1</xref>.</p>
<p>Fever or chills, cough, sore throat, nausea, rhinorrhea, diarrhea, weariness, exhaustion, headache, dyspnea, myalgia, dysgeusia, or anosmia are the prevalent symptoms, especially if the patients have been exposed recently [<xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref14">14</xref>]. In the majority of patients, the sickness is self-limiting, but in some cases, patients require hospitalization due to hypoxia, which is more common among those with concurrent conditions. Acute respiratory distress syndrome affects around 5 % of the population, and the infected symptomatic patient requires oxygen supplement intubation and other invasive treatment. Currently, there are many studies aiming at the development of vaccines and antiviral medicines for COVID-19. There are some antiviral drugs being prescribed for treating the COVID-19 infection, including Remdesivir, steroids, tocilizumab, favipiravir, ivermectin, lopinavir /ritonavir [<xref ref-type="bibr" rid="ref15 ref16 ref17">15-17</xref>]. Studies revealed that in comparison to other antiviral drugs, Remdesivir showed a better therapeutic effect. A summary of the current treatment options and clinical features of COVID-19 is provided here, along with the role and progress of nanotechnology-based photodynamic therapy in treating infections.</p>
</sec>
<sec id="sec1-2" sec-type="methods">
<title>Methods</title>
<p>A comprehensive search initially yielded a total number of 275 research articles related to the topic, while some specific keywords like 'Nano-mediated PDT', 'PDT for SARS-CoV-2', and 'Nanotechnology in treatment for SARS-CoV-2' were placed in the online database search. Popular electronic databases such as Scopus, Google Scholar, MEDLINE, Embase, PubMed, and Web of Science were used to collect the articles. Instead of merely using PDT as a keyword, PDT was sometimes referred to as 'photodynamic therapy'. After conducting an abstract screening, 198 articles were selected for further consideration. During the full-text screening, 80 articles were excludeed leaving a subset of relevant articles. Additionally, 18 more papers were deemed unsuitable for inclusion in the manuscript during the data extraction process. While prioritizing articles published from 2018 onwards, a few older references were included to furnish the basic concepts utilizing their valuable and unchanging particulars.</p>
</sec>
<sec id="sec1-3">
<title>Vaccines</title>
<p>Vaccine development is a difficult, time-consuming, and expensive procedure. Trained professionals are required with multiple procedures, pauses for inspections, and data analysis to develop licensed work. The development of an ideal vaccine needs technical flexibility and adaptability with large-scale manufacturing, high purity, easy transportation, and storage. The foremost considerations while designing a vaccine are the stability, route of administration, and adverse effects. The present efforts are to create a vaccination against COVID-19 as quickly as possible. The most challenging aspect of vaccine designing is identifying the causative agent, wherein the incidence of COVID-19 was not found quickly after the outbreak began [<xref ref-type="bibr" rid="ref18">18</xref>]. Based on the knowledge gathered from past epidemics of corona-mediated viral infections, specifically from SARS-CoV and MERS-CoV, many international funding organizations for vaccines and immunization are sponsoring to support and continue the creative attempts to design a vaccine. The protein contents of SARS-CoV-2, as well as their mode of action, had already been recognized. SARS-CoV-2 is a positive sensed and single-stranded RNA virus [<xref ref-type="bibr" rid="ref19">19</xref>]. Proteins E, S, M, and N are some structural and functional protein that surrounds the SARS-CoV-2 virus [<xref ref-type="bibr" rid="ref20">20</xref>,<xref ref-type="bibr" rid="ref21">21</xref>]. The current approaches for designing vaccines constitute viral vector-based vaccines, virus-like protein particles (VLP), viral protein S subunit, and novel non-viral nucleic acid (RNA and DNA) based vaccines [<xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref23">23</xref>]. Due to the previous research in 2003 for developing a vaccine against SARS-CoV by targeting the S subunit, vaccination against SARS-CoV-2 went straight into clinical research- human trial with the previous results [<xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref25">25</xref>].</p>
<p>SARS-coronavirus possess unique RNA proofreading capabilities by 3'- 5' exonuclease activities of NSP12 and NSP14 [<xref ref-type="bibr" rid="ref26">26</xref>]. This decides the two major characteristics of the virus: (1) high replication efficiency and (2) minimal new mutation rate and estimated to be around 2x10<sup>5</sup>. Due to the unusual faults during viral genome replication, it may sometimes result in the formation of variations, which greatly impacts the virus infectivity, causes antigenic drift, and alters the host's response towards the viral antigen. This antigen drift could hinder the construction of a vaccine that is active for a longer duration. Single amino acid mutation in the S protein, like D614G, has emerged as the widespread genotype in the present pandemic. According to preliminary studies, the D614G variation does not affect the effectiveness of vaccines targeting the S protein, as this variation has no impact on the antigenic characteristics of the S protein [<xref ref-type="bibr" rid="ref27">27</xref>,<xref ref-type="bibr" rid="ref28">28</xref>].</p>
<sec id="sec2-1">
<title>DNA-based vaccine</title>
<p>DNA-based COVID-19 vaccine is a defining attempt for nucleic acid technology, mostly disregarded throughout the pandemic. A novel COVID-19 vaccine entices the immune system against the SARS-CoV-2 virus by using circular strands of DNA [<xref ref-type="bibr" rid="ref29">29</xref>]. Researchers have hailed the clearance of DNA vaccines for humans. DNA vaccines have a number of attractive properties that include easy production with excellent quality, cost-effectiveness, high safety concerns, and stability [<xref ref-type="bibr" rid="ref30">30</xref>]. DNA vaccines can be delivered via intramuscular or intradermal inoculation, as well as electroporation. The immunogenicity and tolerance rate of DNA vaccines were found to be huge; thus, they are being developed to combat various infections. Researchers developed a DNA vaccine in order to decrease the level of viral RNA, which was tested against a SARS-CoV-2 immunized monkey model and shown to exhibit an effective immune response [<xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref>]. Similarly, recombinant adenovirus expressing whole spike protein vaccine was developed and tested. Many vaccinated candidates displayed T-cell responses and dose-dependent antibody activity. The adverse effects were moderate, and no severe complications were reported [<xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref34">34</xref>].</p>
</sec>
<sec id="sec2-2">
<title>mRNA-based vaccine</title>
<p>The mRNA vaccine largely varies from conventional vaccines, where it stimulates the host immune system by using any one of two major components: an inactivated organism or an antigen, which is the protein of that organism [<xref ref-type="bibr" rid="ref35">35</xref>]. An RNA polymerase was used to transcribe an ORF-containing mRNA from a DNA template. The advantages of mRNA-based vaccinations include simplicity, safety, and scalability of laboratory manufacturing, depending on the translational machinery of the host, and loss of integration in the genome [<xref ref-type="bibr" rid="ref36">36</xref>]. However, there is a significant barrier to successful delivery, including the stability of mRNA during storage, the stability inside the host, an unpredictable immune response, and storage instability until frozen. Vaccination with mRNA is considered a relatively productive and time-saving option against COVID-19. As a result, RNA has emerged as the key component in the development of vaccines against COVID-19. Spike protein is the prime target for mRNA vaccines, as the structural aspect is similar to SARS-CoV and SARS-CoV-2 [<xref ref-type="bibr" rid="ref37">37</xref>,<xref ref-type="bibr" rid="ref38">38</xref>]. Neutralizing activity of antibodies against the N-terminal and Receptor binding domain (RBD) of S protein was studied in COVID-19 patients and proved that these are the components that hinder their use as the target for vaccine development [<xref ref-type="bibr" rid="ref39">39</xref>,<xref ref-type="bibr" rid="ref40">40</xref>]. The major problem is the entry route of SARS-CoV-2 into the cell with a mechanism that is not dependent on ACE2. RNA vaccine has some more challenges like the stability of mRNA, absorption efficiency by the host cells, and release rate into the cell cytoplasm to target the protein [<xref ref-type="bibr" rid="ref41">41</xref>].</p>
</sec>
<sec id="sec2-3">
<title>Nanoparticle used for vaccine</title>
<p>RNA and DNA vaccines can generate immunity against a specific disease while reducing the risk of infection. The delivery of these immunogens to the site of action, together with other immunogens, as part of a vaccination regimen is a major difficulty. The limitations can be resolved by employing an efficient delivery method to deliver the vaccine to the target location and the adjuvant while preserving it against deterioration in a hostile environment. The delivery mechanism should have an immunogenic effect that lasts without causing any negative effects. Nanoparticles based delivery systems are popular nowadays for theranostic applications [<xref ref-type="bibr" rid="ref42 ref43 ref44 ref45">42-45</xref>]. Nano-delivery methods might meet the criteria and allow for the long-term sustained release of vaccine molecules without being damaged by proteases [<xref ref-type="bibr" rid="ref46">46</xref>,<xref ref-type="bibr" rid="ref47">47</xref>]. The use of nanocarriers for vaccine components improves cellular absorption, resulting in enhanced innate, humoral, cellular, and mucosal immune responses [<xref ref-type="bibr" rid="ref48">48</xref>,<xref ref-type="bibr" rid="ref49">49</xref>]. Nanoparticle vaccines are powerful, safe, and simple to make. In comparison to vaccinations that retain parts of the virus, attenuated viral vaccines are more effective, but they take a longer time to reach the site, have special storage conditions (subzero temperatures), and might carry the risk of adverse effects. Vaccines containing nucleic acids (RNA and DNA) are easy to make, but they are expensive and may require many doses. There have been reports of nanoparticle vaccinations for COVID-19 eliciting an effective immunological response in mice after a single dosage. The mRNA is encapsulated in lipid-based nanoparticles or other substances and can be injected into the host via IM (Intramuscular) route to increase its stability and prevent it from rapid degradation by host ribonucleases [<xref ref-type="bibr" rid="ref50">50</xref>]. The mRNA-1273 vaccine is the first mRNA vaccine with lipid microparticle capsule-based modified viral RNA against COVID-19 [<xref ref-type="bibr" rid="ref51">51</xref>].</p>
</sec>
</sec>
<sec id="sec1-4">
<title>Diagnosis</title>
<p>The diagnosis is made depending on a range of factors, including epidemiology, clinical findings, <italic>in vitro</italic> assays, and the nucleic acid amplification test. The most accurate assay for detecting SARS-CoV-2 is presently being reliably detected by real-time reverse transcriptase-PCR (rRT-PCR), which is reinforced by other auxiliary assays like serology and radiography [<xref ref-type="bibr" rid="ref52">52</xref>]. Commercial kits have been brought into the field by validating numerous molecular and immunological aspects by the FDA (Food and Drug Administration) and ICMR (Indian Council of Medical Research) [<xref ref-type="bibr" rid="ref53">53</xref>,<xref ref-type="bibr" rid="ref54">54</xref>]. However, given the drawbacks in terms of sensitivity and specificity, as well as the gaps in monitoring the virus spread, there is an urgent need to develop a novel diagnostic technique that is both rapid and accurate with high safety concerns to deploy them on a wide scale in order to halt the global outbreak.</p>
<sec id="sec2-4">
<title>Nanoparticle-based diagnosis</title>
<p>Because of its simplicity, high sensitivity, and high specificity based on exponential growth in RNA generated throughout the operation, RT-PCR was used in most viral RNA detection procedures [<xref ref-type="bibr" rid="ref55">55</xref>]. Although RT-PCR techniques are commonly accepted as the gold standard for coronavirus detection, they do have certain drawbacks, such as limited extraction efficiency, time-consuming procedure, and false-positive result due to contamination. To improve the method of detection of virus efficacy, ultra-small nanoparticles have been used not only in RT-PCR but also in other viral detection techniques such as an enzyme-linked immunosorbent assay (ELISA) and RT-LAMP (Reverse transcription loop-mediated isothermal amplification) [<xref ref-type="bibr" rid="ref56">56</xref>,<xref ref-type="bibr" rid="ref57">57</xref>]. Metal nanoparticles, carbon nanotubes, silica nanoparticles, quantum dots (QDs), and polymeric nanoparticles have been examined in the context of viral detection. Colorimetric, fluorescent, electrochemical, and optical imaging techniques are used as most diagnostic methods. Metal nanoparticles and QDs with distinct optical characteristics offer increased sensitivity for optical biosensing, and magnetic properties are used in the extraction process of the virus [<xref ref-type="bibr" rid="ref58 ref59 ref60 ref61">58-61</xref>]. Nanoparticle-based viral detection method has been identified as a suitable target for SARS-CoV-2. Nanoparticles will play a major role in enhancing not only coronavirus detection efficiency but also biological pathogen diagnoses, with improvement in study and development (<xref ref-type="fig" rid="fig002">Figure 2</xref>) [<xref ref-type="bibr" rid="ref62">62</xref>,<xref ref-type="bibr" rid="ref63">63</xref>].</p>
</sec>
</sec>
<sec id="sec1-5">
<title>Treatment</title>
<p>Researchers are already into the development of a variety of pharmaceuticals to combat COVID-19. Drugs being investigated for the treatment against COVID-19 follow either one of the two mechanisms: (1) to control the symptoms caused or (2) to inactivate by targeting the replication cycle of the virus [<xref ref-type="bibr" rid="ref64">64</xref>,<xref ref-type="bibr" rid="ref65">65</xref>]. Since no proper drug is developed, many antimicrobial drugs are being provided to the patients as a first-line treatment is tabulated below (<xref ref-type="table" rid="table001">Table 1</xref>).</p>
</sec>
<sec id="sec1-6">
<title>Photodynamic therapy (PDT)</title>
<p>The use of photosensitizer (PS), light, and molecular oxygen (O<sub>2</sub>) has enhanced through time, and the term PDT has developed [<xref ref-type="bibr" rid="ref66">66</xref>,<xref ref-type="bibr" rid="ref67">67</xref>]. PDT is a non-invasive emerging therapeutic method that works by activating the photosensitizer (PS) with a certain wavelength of light. In the process of illumination, the PS transfers its energy to the molecular oxygen when it is stimulated, which in turn generates cytotoxic molecules, namely reactive oxygen species (ROS), which have the ability to disrupt the cell wall of the microorganisms in a variety of diseases and infections. The singlet oxygen produced can efficiently oxidize the main cellular macromolecules that destroy the microorganisms [<xref ref-type="bibr" rid="ref67">67</xref>]. This therapy has been implemented to treat cancer, bacterial infection, fungal and viral diseases, as well as photodynamic diagnostics in the area of dentistry. PDT does not pose harmful risks to the biological system. It is clear that compared with traditional treatment modalities, PDT has its advantages due to its limited invasiveness and negligible cumulative toxicity. Therefore, PDT aims to boost the quality of life of patients. Jablonski's schematic diagram displays the intricacies of photodynamic activity, defined as an array of photophysical and photochemical reactions (<xref ref-type="fig" rid="fig003">Figure 3</xref>). PDT needs the synchronous combination of the PS, proper wavelength of visible light, and molecular oxygen. The photosensitizing molecule possesses two electrons (opposite spins) in its ground state, and the symbol S<sub>0</sub> is denoted as total spin, which is zero. The reaction includes absorption of light by PS and triggers an array of photochemical reactions leading to ROS production. The ROS, also termed singlet oxygen (<sup>1</sup>O<sub>2</sub>) in the lowest energy state, can cause serious oxidative injury to pathogenic microorganisms like viruses, bacteria, fungi, and parasites. During the PDT process, it produces other <sup>1</sup>O<sub>2</sub>, such as superoxide ions (O<sub>2</sub>-&#x2022;), hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), and hydroxyl radicals (OH&#x2022;) [<xref ref-type="bibr" rid="ref68">68</xref>,<xref ref-type="bibr" rid="ref69">69</xref>].</p>
<p>According to the mechanism of PDT, the PS excites from the low energy state to a higher energy state with a limited life cycle ranging from nanoseconds to less after the absorption of light. After excitation, any one of the two mechanisms can occur: (1) fall back to grounds state and emits fluorescence or (2) reach triplet state by undergoing the crossing in intersystem. The triplet state lifetime provides adequate time for the excited PS to interact with the oxygen molecule or other tissue substrates [<xref ref-type="bibr" rid="ref70">70</xref>]. During this mechanism, the proton gets transferred due to this direct interaction between triplet PS and substrate, which leads to the formation of radical anion or cation, which in turn tends to react with molecular oxygen and produces oxygenated compounds like superoxide anion radical, hydrogen peroxides, and hydroxide radicals. This method is termed a type 1 reaction of PDT. In type II reaction, the direct energy transfer of the excited PS to molecular oxygen, in turn, forms singlet oxygen (<sup>1</sup>O<sub>2</sub>). Both the type I and type II reactions involve the formation of some final products, which decides the therapeutic index of the whole therapy. In a PDT reaction, both the types I and II reactions can result simultaneously [<xref ref-type="bibr" rid="ref71">71</xref>,<xref ref-type="bibr" rid="ref72">72</xref>]. In accordance with the category of PS, the amount of substrate in tissues, and the molecular oxygen concentration, the occurrence rate of type I and type II reaction differs. Most of the studies suggest that <sup>1</sup>O<sub>2</sub> plays a significant role in PDT.</p>
<sec id="sec2-5">
<title>PDT for the treatment of viral infections</title>
<p>Infections are one of the major public health issues being studied by diverse research teams. The number of novel antimicrobials and their target structures has steadily reduced, so there is a need for alternative infection treatment [<xref ref-type="bibr" rid="ref73">73</xref>,<xref ref-type="bibr" rid="ref74">74</xref>]. Photodynamic therapy is considered an effective and alternative treatment option that has been shown to have great potential against a variety of disease states caused by an infectious microorganism and may be a viable option for treatment against SARS-CoV-2 infections, which can be studied further to improve the treatment success rate. The outbreak of COVID-19 has expanded enormously due to the insufficiency of immunizations also therapeutic interventions for the prevention and management of viral infections. Because of the severity and urgency of COVID-19, a new technique needs to be developed for the prevention and treatment of the virus [<xref ref-type="bibr" rid="ref75">75</xref>,<xref ref-type="bibr" rid="ref76">76</xref>]. Antiviral Photodynamic Therapy (aPDT) is likely to be useful as a potential therapy for coronavirus inhibition and reduction. The effectiveness of aPDT in inactivating mammalian viruses has been established in several research outcomes (<xref ref-type="table" rid="table002">Table 2</xref>).</p>
<p>Examples such as Adenovirus, Hepatitis viruses A, B, and C, HIV (Human immunodeficiency virus), parvovirus B19, Herpes virus, etc., causing infections have been studied to get treated with PDT, and certain studies have found that the viruses with the outer envelope are more susceptible to aPDT than non-enveloped viruses. aPDT is being utilized for inactivating multiple viruses in a variety of biological fluids, including blood. Treating superficial viral lesions with aPDT is also very effective [<xref ref-type="bibr" rid="ref77">77</xref>]. The ROS will be produced when a photoinactivation method is performed on a variety of significant biomolecule targets, such as DNA, lipids, and proteins. ROS produces oxidative stress and causes irreparable damage to the cellular structure of the virus. This oxidative stress induces apoptosis and necrosis to kill the virus without causing damage to the surrounding healthy tissues. Both intracellular as well as extracellular ROS can be released by aPDT. PS is considered as one of the essential components of PDT. Colors of porphycenes and phenothiazines, such as azure, Methylene blue (MB), Toluidine Blue O (TBO), chlorine, porphyrin, and phthalocyanine derivatives are suitable as PS for the aPDT [<xref ref-type="bibr" rid="ref78">78</xref>]. COVID-19 is now treated with chloroquine (C<sub>18</sub>H2<sub>6</sub>ClN<sub>3</sub>), and it has a structural similarity with MB (C<sub>16</sub>H<sub>18</sub>ClN<sub>3</sub>S). According to the preliminary data from a recent trial, MB might be an effective PS for the therapy for flu-like conditions like COVID-19. Studies proved that MB efficiently inhibits the spike protein and ACE2 (Angiotensin-Converting enzyme 2) receptor of SARS-CoV-2 to inactivate the viral replication [<xref ref-type="bibr" rid="ref79">79</xref>].</p>
</sec>
<sec id="sec2-6">
<title>Nanoformulated PDT</title>
<p>Management of SARS-CoV-2 infections is still in progress, and some vaccines are in use in an emergency. Nanotechnology has been employed to improve the efficacy of those vaccines to target COVID-19 (<xref ref-type="table" rid="table003">Table 3</xref>). Researchers currently focus on nanomaterials-based antiviral photodynamic therapy treatment. That has been proven as an innovative strategy to inhibit bacterial and viral infections like papilloma and herpes. Nanomaterials can improve solubility, increase blood circulation time, limit enzymatic degradation, lesser unwanted side effects, and improve medication bioavailability [<xref ref-type="bibr" rid="ref76">76</xref>]. In antimicrobial PDT, employing nanoparticles can improve the solubility, photophysics, and photochemistry of photosensitizers with targeting features.</p>
<p>In this process, PS can be encapsulated in different nanostructures or nanoparticles like micelles, reverse micelles, liposomes, metal and metal-oxide nanoparticles, polymer nanoparticles, carbon nanotubes, and ceramic-based nanoparticles. In this regard, the dendrimers are also promising to conjugate or load the PS molecules for better aPDT [<xref ref-type="bibr" rid="ref80">80</xref>].</p>
<p>The branch-like structure and lipophilicity of dendrimers enhance the solubility of PS and, at the same time, help in the improvement of cellular uptake. The other advantages include the higher production of ROS in nanoformulations. PS molecules are well separated by the nanostructures like liposomes, dendrimers, etc., to stop self-quenching [<xref ref-type="bibr" rid="ref81">81</xref>].</p>
<p>Recently up-conversion nanoparticles-based PDT has gained popularity for its absorption band in the NIR zone. After absorbing NIR radiation, the up-conversion nanoparticles (UCNP) emit visible light, which is absorbed by the PS molecules to react with molecular oxygen for the generation of ROS [<xref ref-type="bibr" rid="ref82">82</xref>,<xref ref-type="bibr" rid="ref83">83</xref>]. Lim et al. showed that the UCNP-mediated ROS generation could inactivate the dengue virus serotype 2 (DENV2) and adenovirus type 5 (Ad5V) [<xref ref-type="bibr" rid="ref84">84</xref>]. This strategy can be well applicable to the management of SARS-CoV-2 infections. The surface modification strategy of nanoformulated PS with targeting moieties as specific ligands or antibodies can help to increase the specificity of aPDT against COVID-19 protecting healthy cells [<xref ref-type="bibr" rid="ref85">85</xref>].</p>
<p>Carbon nanotubes have been proposed for use as novel photosensitizers in photodynamic therapy. Carbon nanotubes that have been functionalized, conjugated, or encapsulated with other photosensitizers are powerful for PDT against infectious diseases. Banerjee <italic>et al.</italic> investigated PpIX conjugated to multi-walled and single-walled carbon tubes, and this conjugation was found to inhibit the influenza A virus [<xref ref-type="bibr" rid="ref86">86</xref>]. For recently discovered covid-19, surface-modified nanoparticles could target the receptor present on the lung cell with the particular antibodies causing the infected cells to be destroyed by aPDT. Recent research suggests that aPDT may be effective in the treatment of Covid-19 with lesser side effects and pharmacological interactions.</p>
</sec>
</sec>
<sec id="sec1-7">
<title>Computational approach</title>
<p>The computational approach of the combination of chemistry and biology has evolved as one of the essential parts of drug discovery. New lead molecules can be significantly developed by computational approach at minimal cost within a limited period of time. The efficacy of the method of testing and analyzing the developed products can be effectively improved [<xref ref-type="bibr" rid="ref87">87</xref>]. Certain tools like molecular docking, virtual screening, protein modeling, ADMET (adsorption, distribution, metabolism, excretion, and toxicity), molecular dynamics, and QSAR (quantitative structure-activity relationship) are capable of providing valid predictions and has raised as key part of the computational approach. The photochemical reactivity of PS needs to be well understood for an effective yield and for which molecular orbital calculations are used as they can predict the mechanism of action and anticipate the results. Wang <italic>et al.</italic> recently designed a PS for PDT as cancer treatment using computer-aided drug designing [<xref ref-type="bibr" rid="ref88">88</xref>]. The team used two drugs where the similarity in molecular properties and the intermolecular interactions between the two drugs were identified with a dynamic simulation model and molecular docking, respectively. The efficiency of the particle for cancer therapy was greatly improved due to the screening test done via a computational approach [<xref ref-type="bibr" rid="ref88">88</xref>]. Fedorov <italic>et al</italic>. utilized coarse graining molecular dynamic method to understand the molecular interaction between the developed PS and the surface structure of the virus, and with the same, the major and minor binding sites were also studied [<xref ref-type="bibr" rid="ref89">89</xref>]. Similarly, Sharshov <italic>et al</italic>. studied the chemistry behind the interaction between PS and virus using dynamic simulation methods [<xref ref-type="bibr" rid="ref90">90</xref>]. <xref ref-type="table" rid="table004">Table 4</xref> summarizes the other computational approaches to formulate the PS.</p>
</sec>
<sec id="sec1-8">
<title>Conclusion and future perspective</title>
<p>COVID-19 is rapidly spreading around the world, resulting in an increase in affected cases and deaths. We are confronted with many unknowns, and we must continue to monitor and research. Until now, no appropriate therapy against SARS-CoV-2 for a complete cure is available. To resolve this issue, researchers are focusing on developing viable vaccinations and treatments. Nanotechnology is now emerging as a potential field for diagnosing and treating several disorders. Due to the small size and exponential surface chemistry, the nanoparticle can be an effective tool in manufacturing vaccines and developing treatment strategies against COVID-19 infection. PDT is a non-invasive therapeutic strategy based on the activation of a PS with the help of light in a certain wavelength. In PDT, the nanoparticle can act as a drug carrier or a drug by itself. In order to overcome the drawback of PS, nanoparticles can be used as a carrier of PS. Studies revealed nanoparticle-based antiviral medicines and nano-based-PDT would sufficiently combat the COVID-19 pandemic.</p>
</sec>
</body>
<back>
<fn-group>
<fn><p><italic><bold>Authors Contribution</bold>: PP &#x0026; KH collected all required data and wrote the initial draft. NAE, PG, and KG compiled it with additional data. The concept, overall representation, and final version were prepared by AG.</italic></p></fn>
<fn fn-type="conflict"><p><italic><bold>Conflict of interest</bold>: The authors declare that there is not any conflict of interest.</italic></p></fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p><italic>Authors acknowledge CARE for financial and infrastructural support. PP, KR &#x0026; PG acknowledge CARE for fellowships too.</italic></p>
</ack>
<ref-list>
<title>References</title>
<ref id="ref1"><label>[1]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valsamatzi-Panagiotou</surname><given-names>A.</given-names></name><name><surname>Penchovsky</surname><given-names>R.</given-names></name></person-group> <article-title>Environmental factors influencing the transmission of the coronavirus 2019: a review</article-title>. <source>Environmental Chemistry Letters</source> <volume>20</volume> (<year>2022</year>) <fpage>1603</fpage>-<lpage>1610</lpage>. <comment>https://doi.org/10.1007/s10311-022-01418-9.</comment> <pub-id pub-id-type="doi">10.1007/s10311-022-01418-9</pub-id></mixed-citation></ref>
<ref id="ref2"><label>[2]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girigoswami</surname><given-names>A.</given-names></name><name><surname>Girigoswami</surname><given-names>K.</given-names></name></person-group> <article-title>Versatile applications of nanosponges in biomedical field: a glimpse on SARS-CoV-2 management</article-title>. <source>BioNanoScience</source> <volume>12</volume> (<year>2022</year>) <fpage>1018</fpage>-<lpage>1031</lpage>. <comment>https://doi.org/10.1007/s12668-022-01000-1.</comment> <pub-id pub-id-type="doi">10.1007/s12668-022-01000-1</pub-id></mixed-citation></ref>
<ref id="ref3"><label>[3]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Sayyad</surname><given-names>G.S.</given-names></name><name><surname>Elfadil</surname><given-names>D.</given-names></name><name><surname>Gaballah</surname><given-names>M.S.</given-names></name><name><surname>El-Sherif</surname><given-names>D.M.</given-names></name><name><surname>Abouzid</surname><given-names>M.</given-names></name><name><surname>Nada</surname><given-names>H.G.</given-names></name><name><surname>Khalil</surname><given-names>M.S.</given-names></name><name><surname>Ghorab</surname><given-names>M.A.</given-names></name></person-group> <article-title>Implication of nanotechnology to reduce the environmental risks of waste associated with the COVID-19 pandemic</article-title>. <source>RSC Advances</source> <volume>13</volume> (<year>2023</year>) <fpage>12438</fpage>-<lpage>12454</lpage>. <comment>https://doi.org/10.1039/D3RA01052J.</comment> <pub-id pub-id-type="doi">10.1039/D3RA01052J</pub-id></mixed-citation></ref>
<ref id="ref4"><label>[4]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rademaker</surname><given-names>M.</given-names></name><name><surname>Baker</surname><given-names>C.</given-names></name><name><surname>Foley</surname><given-names>P.</given-names></name><name><surname>Sullivan</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name></person-group> <article-title>Advice regarding COVID&#x002D;19 and use of immunomodulators, in patients with severe dermatological diseases</article-title>. <source>The Australasian Jjournal of Dermatology</source> (<year>2020</year>). <comment>https://doi.org/10.1111/ajd.13295.</comment> <pub-id pub-id-type="doi">10.1111/ajd.13295</pub-id></mixed-citation></ref>
<ref id="ref5"><label>[5]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aftab</surname><given-names>S.</given-names></name><name><surname>Iqbal</surname><given-names>M.Z.</given-names></name><name><surname>Hussain</surname><given-names>S.</given-names></name><name><surname>Hegazy</surname><given-names>H.H.</given-names></name></person-group> <article-title>Recent Advances in Nanomaterials&#x002D;Based FETs for SARS&#x002D;CoV&#x002D;2 (COVID&#x002D;19 Virus) Diagnosis</article-title>. <source>Advanced Functional Materials</source> (<year>2023</year>) <fpage>2301007</fpage>. <comment>https://doi.org/10.1002/adfm.202301007.</comment> <pub-id pub-id-type="doi">10.1002/adfm.202301007</pub-id></mixed-citation></ref>
<ref id="ref6"><label>[6]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agharezaei</surname><given-names>N.</given-names></name><name><surname>Forouzesh</surname><given-names>F.</given-names></name></person-group> <article-title>SARS-COV-2: history, genetics, and treatment</article-title>. <source>Journal of Arak University of Medical Sciences</source> <volume>23</volume> (<year>2020</year>) <fpage>666</fpage>-<lpage>685</lpage>. <comment>https://doi.org/10.32598/JAMS.23.COV.5712.2.</comment> <pub-id pub-id-type="doi">10.32598/JAMS.23.COV.5712.2</pub-id></mixed-citation></ref>
<ref id="ref7"><label>[7]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tharayil</surname><given-names>A.</given-names></name><name><surname>Rajakumari</surname><given-names>R.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Choudhary</surname><given-names>M.D.</given-names></name><name><surname>Palit</surname><given-names>P.</given-names></name><name><surname>Thomas</surname><given-names>S.</given-names></name></person-group> <article-title>New insights into application of nanoparticles in the diagnosis and screening of novel coronavirus (SARS-CoV-2)</article-title>. <source>Emergent Materials</source> <volume>4</volume> (<year>2021</year>) <fpage>101</fpage>-<lpage>117</lpage>. <comment>https://doi.org/10.1007/s42247-021-00182-w.</comment> <pub-id pub-id-type="doi">10.1007/s42247-021-00182-w</pub-id></mixed-citation></ref>
<ref id="ref8"><label>[8]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parthasarathy</surname><given-names>P.</given-names></name><name><surname>Vivekanandan</surname><given-names>S.</given-names></name></person-group> <article-title>An extensive study on the COVID-19 pandemic, an emerging global crisis: Risks, transmission, impacts and mitigation</article-title>. <source>Journal of Infection and Public Health</source> <volume>14</volume> (<year>2021</year>) <fpage>249</fpage>-<lpage>259</lpage>. <comment>https://doi.org/10.1016/j.jiph.2020.12.020.</comment> <pub-id pub-id-type="doi">10.1016/j.jiph.2020.12.020</pub-id></mixed-citation></ref>
<ref id="ref9"><label>[9]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>K.</given-names></name><name><surname>Shi</surname><given-names>Z.-L.</given-names></name><name><surname>Zhou</surname><given-names>P.</given-names></name></person-group> <article-title>Bat coronaviruses in China</article-title>. <source>Viruses</source> <volume>11</volume> (<year>2019</year>) <fpage>210</fpage>. <comment>https://doi.org/10.3390/v11030210.</comment> <pub-id pub-id-type="doi">10.3390/v11030210</pub-id></mixed-citation></ref>
<ref id="ref10"><label>[10]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandyopadhyay</surname><given-names>SS</given-names></name><name><surname>Halder</surname><given-names>A.K.</given-names></name><name><surname>Saha</surname><given-names>S.</given-names></name><name><surname>Chatterjee</surname><given-names>P.</given-names></name><name><surname>Nasipuri</surname><given-names>M.</given-names></name><name><surname>Basu</surname><given-names>S.</given-names></name></person-group> <article-title>Assessment of GO-Based Protein Interaction Affinities in the Large-Scale Human&#x2013;Coronavirus Family Interactome</article-title>. <source>Vaccines</source> <volume>11</volume> (<year>2023</year>) <fpage>549</fpage>. <comment>https://doi.org/10.3390/vaccines11030549.</comment> <pub-id pub-id-type="doi">10.3390/vaccines11030549</pub-id></mixed-citation></ref>
<ref id="ref11"><label>[11]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>A.S.</given-names></name><name><surname>Bhattacharya</surname><given-names>K.</given-names></name></person-group> <article-title>An Overview on the Zoonotic Aspects of COVID-19</article-title>. <source>Proceedings of the National Academy of Sciences, India Section B: Biological Sciences</source> (<year>2023</year>) <fpage>1</fpage>-<lpage>5</lpage>. <comment>https://doi.org/10.1007/s40011-023-01445-8.</comment> <pub-id pub-id-type="doi">10.1007/s40011-023-01445-8</pub-id></mixed-citation></ref>
<ref id="ref12"><label>[12]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>T.-D.</given-names></name><name><surname>Zheng</surname><given-names>S.-F.</given-names></name><name><surname>Su</surname><given-names>Y.-Y.</given-names></name><name><surname>Li</surname><given-names>Z.-Y.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Yu</surname><given-names>F.</given-names></name><name><surname>Ge</surname><given-names>S.-X.</given-names></name><name><surname>Zou</surname><given-names>Q.-D.</given-names></name><name><surname>Yuan</surname><given-names>Q.</given-names></name></person-group> <article-title>Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset</article-title>. <source>European Respiratory Journal</source> <volume>56</volume> (<year>2020</year>). <comment>https://doi.org/10.1183/13993003.00763-2020.</comment> <pub-id pub-id-type="doi">10.1183/13993003.00763-2020</pub-id></mixed-citation></ref>
<ref id="ref13"><label>[13]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vahey</surname><given-names>G.M.</given-names></name><name><surname>Marshall</surname><given-names>K.E.</given-names></name><name><surname>McDonald</surname><given-names>E.</given-names></name><name><surname>Martin</surname><given-names>S.W.</given-names></name><name><surname>Tate</surname><given-names>J.E.</given-names></name><name><surname>Midgley</surname><given-names>C.M.</given-names></name><name><surname>Killerby</surname><given-names>M.E.</given-names></name><name><surname>Kawasaki</surname><given-names>B.</given-names></name><name><surname>Herlihy</surname><given-names>R.K.</given-names></name><name><surname>Alden</surname><given-names>N.B.</given-names></name></person-group> <article-title>Symptom profiles and progression in hospitalized and nonhospitalized patients with coronavirus disease, Colorado, USA, 2020</article-title>. <source>Emerging Infectious Diseases</source> <volume>27</volume> (<year>2021</year>) <fpage>385</fpage>. <comment>https://doi.org/10.3201/eid2702.203729.</comment> <pub-id pub-id-type="doi">10.3201/eid2702.203729</pub-id></mixed-citation></ref>
<ref id="ref14"><label>[14]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyerowitz</surname><given-names>E.A.</given-names></name><name><surname>Richterman</surname><given-names>A.</given-names></name><name><surname>Bogoch</surname><given-names>I.I.</given-names></name><name><surname>Low</surname><given-names>N.</given-names></name><name><surname>Cevik</surname><given-names>M.</given-names></name></person-group> <article-title>Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2</article-title>. <source>The Lancet infectious diseases</source> <volume>21</volume> (<year>2021</year>) <fpage>e163</fpage>-<lpage>e169</lpage>. <comment>https://doi.org/10.1016/S1473-3099(20)30837-9.</comment> <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30837-9</pub-id></mixed-citation></ref>
<ref id="ref15"><label>[15]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siordia</surname><given-names>J.A.</given-names></name><name><surname>Bernaba</surname><given-names>M.</given-names></name><name><surname>Yoshino</surname><given-names>K.</given-names></name><name><surname>Ulhaque</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>S.</given-names></name><name><surname>Bernaba</surname><given-names>M.</given-names></name><name><surname>Bergin</surname><given-names>E.</given-names></name></person-group> <article-title>Systematic and statistical review of coronavirus disease 19 treatment trials</article-title>. <source>SN Comprehensive Clinical Medicine</source> <volume>2</volume> (<year>2020</year>) <fpage>1120</fpage>-<lpage>1131</lpage>. <comment>https://doi.org/10.1007/s42399-020-00399-6.</comment> <pub-id pub-id-type="doi">10.1007/s42399-020-00399-6</pub-id></mixed-citation></ref>
<ref id="ref16"><label>[16]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hossen</surname><given-names>M.</given-names></name><name><surname>Barek</surname><given-names>M.A.</given-names></name><name><surname>Jahan</surname><given-names>N.</given-names></name><name><surname>Safiqul Islam</surname><given-names>M.</given-names></name></person-group> <article-title>A review on current repurposing drugs for the treatment of COVID-19: reality and challenges</article-title>. <source>SN Comprehensive Clinical Medicine</source> <volume>2</volume> (<year>2020</year>) <fpage>1777</fpage>-<lpage>1789</lpage>. <comment>https://doi.org/10.1007/s42399-020-00485-9.</comment> <pub-id pub-id-type="doi">10.1007/s42399-020-00485-9</pub-id></mixed-citation></ref>
<ref id="ref17"><label>[17]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagliano</surname><given-names>P.</given-names></name><name><surname>Scarpati</surname><given-names>G.</given-names></name><name><surname>Sellitto</surname><given-names>C.</given-names></name><name><surname>Conti</surname><given-names>V.</given-names></name><name><surname>Spera</surname><given-names>A.M.</given-names></name><name><surname>Ascione</surname><given-names>T.</given-names></name><name><surname>Piazza</surname><given-names>O.</given-names></name><name><surname>Filippelli</surname><given-names>A.</given-names></name></person-group> <article-title>Experimental pharmacotherapy for COVID-19: the latest advances</article-title>. <source>Journal of Experimental Pharmacology</source> <volume>13</volume> (<year>2021</year>) <fpage>1</fpage>. <comment>https://doi.org/10.2147/JEP.S255209.</comment> <pub-id pub-id-type="doi">10.2147/JEP.S255209</pub-id></mixed-citation></ref>
<ref id="ref18"><label>[18]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soufi</surname><given-names>G.J.</given-names></name><name><surname>Hekmatnia</surname><given-names>A.</given-names></name><name><surname>Nasrollahzadeh</surname><given-names>M.</given-names></name><name><surname>Shafiei</surname><given-names>N.</given-names></name><name><surname>Sajjadi</surname><given-names>M.</given-names></name><name><surname>Iravani</surname><given-names>P.</given-names></name><name><surname>Fallah</surname><given-names>S.</given-names></name><name><surname>Iravani</surname><given-names>S.</given-names></name><name><surname>Varma</surname><given-names>R.S.</given-names></name></person-group> <article-title>SARS-CoV-2 (COVID-19): new discoveries and current challenges</article-title>. <source>Applied Sciences</source> <volume>10</volume> (<year>2020</year>) <fpage>3641</fpage>. <comment>https://doi.org/10.3390/app10103641.</comment> <pub-id pub-id-type="doi">10.3390/app10103641</pub-id></mixed-citation></ref>
<ref id="ref19"><label>[19]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranjbar</surname><given-names>R.</given-names></name><name><surname>Mahmoodzadeh Hosseini</surname><given-names>H.</given-names></name><name><surname>Safarpoor Dehkordi</surname><given-names>F.</given-names></name></person-group> <article-title>A review on biochemical and immunological biomarkers used for laboratory diagnosis of SARS-CoV-2 (COVID-19)</article-title>. <source>The Open Microbiology Journal</source> <volume>14</volume> (<year>2020</year>). <comment>https://doi.org/10.2174/1874434602014010290.</comment> <pub-id pub-id-type="doi">10.2174/1874434602014010290</pub-id></mixed-citation></ref>
<ref id="ref20"><label>[20]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>X.-f.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>S.-w.</given-names></name></person-group> <article-title>Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19</article-title>. <source>Acta Pharmacologica Sinica</source> <volume>41</volume> (<year>2020</year>) <fpage>1141</fpage>-<lpage>1149</lpage>. <comment>https://doi.org/10.1038/s41401-020-0485-4.</comment> <pub-id pub-id-type="doi">10.1038/s41401-020-0485-4</pub-id></mixed-citation></ref>
<ref id="ref21"><label>[21]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlson</surname><given-names>C.R.</given-names></name><name><surname>Asfaha</surname><given-names>J.B.</given-names></name><name><surname>Ghent</surname><given-names>C.M.</given-names></name><name><surname>Howard</surname><given-names>C.J.</given-names></name><name><surname>Hartooni</surname><given-names>N.</given-names></name><name><surname>Safari</surname><given-names>M.</given-names></name><name><surname>Frankel</surname><given-names>A.D.</given-names></name><name><surname>Morgan</surname><given-names>D.O.</given-names></name></person-group> <article-title>Phosphoregulation of phase separation by the SARS-CoV-2 N protein suggests a biophysical basis for its dual functions</article-title>. <source>Molecular Cell</source> <volume>80</volume> (<year>2020</year>) <fpage>1092</fpage>-<lpage>1103</lpage>. <comment>e1094. https://doi.org/10.1016/j.molcel.2020.11.025.</comment> <pub-id pub-id-type="doi">10.1016/j.molcel.2020.11.025</pub-id></mixed-citation></ref>
<ref id="ref22"><label>[22]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schott</surname><given-names>J.W</given-names></name><name><surname>Galla</surname><given-names>M.</given-names></name><name><surname>Godinho</surname><given-names>T.</given-names></name><name><surname>Baum</surname><given-names>C.</given-names></name><name><surname>Schambach</surname><given-names>A.</given-names></name></person-group> <article-title>Viral and non-viral approaches for transient delivery of mRNA and proteins</article-title>. <source>Current Gene Therapy</source> <volume>11</volume> (<year>2011</year>) <fpage>382</fpage>-<lpage>398</lpage>. <comment>https://doi.org/10.2174/156652311797415872.</comment> <pub-id pub-id-type="doi">10.2174/156652311797415872</pub-id></mixed-citation></ref>
<ref id="ref23"><label>[23]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velikova</surname><given-names>T.</given-names></name><name><surname>Georgiev</surname><given-names>T.</given-names></name></person-group> <article-title>SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis</article-title>. <source>Rheumatology International</source> <volume>41</volume> (<year>2021</year>) <fpage>509</fpage>-<lpage>518</lpage>. <comment>https://doi.org/10.1007/s00296-021-04792-9.</comment> <pub-id pub-id-type="doi">10.1007/s00296-021-04792-9</pub-id></mixed-citation></ref>
<ref id="ref24"><label>[24]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>Y.-F.</given-names></name><name><surname>Chien</surname><given-names>C.-S.</given-names></name><name><surname>Yarmishyn</surname><given-names>A.A.</given-names></name><name><surname>Lin</surname><given-names>Y.-Y.</given-names></name><name><surname>Luo</surname><given-names>Y.-H.</given-names></name><name><surname>Lin</surname><given-names>Y.-T.</given-names></name><name><surname>Lai</surname><given-names>W.-Y.</given-names></name><name><surname>Yang</surname><given-names>D.-M.</given-names></name><name><surname>Chou</surname><given-names>S.-J.</given-names></name><name><surname>Yang</surname><given-names>Y.-P.</given-names></name></person-group> <article-title>A review of SARS-CoV-2 and the ongoing clinical trials</article-title>. <source>International Journal of Molecular Sciences</source> <volume>21</volume> (<year>2020</year>) <fpage>2657</fpage>. <comment>https://doi.org/10.3390/ijms21072657.</comment> <pub-id pub-id-type="doi">10.3390/ijms21072657</pub-id></mixed-citation></ref>
<ref id="ref25"><label>[25]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oroojalian</surname><given-names>F.</given-names></name><name><surname>Haghbin</surname><given-names>A.</given-names></name><name><surname>Baradaran</surname><given-names>B.</given-names></name><name><surname>Hemmat</surname><given-names>N.</given-names></name><name><surname>Shahbazi</surname><given-names>M.-A.</given-names></name><name><surname>Baghi</surname><given-names>H.B.</given-names></name><name><surname>Mokhtarzadeh</surname><given-names>A.</given-names></name><name><surname>Hamblin</surname><given-names>M.R.</given-names></name></person-group> <article-title>Novel insights into the treatment of SARS-CoV-2 infection: an overview of current clinical trials</article-title>. <source>International Journal of Biological Macromolecules</source> <volume>165</volume> (<year>2020</year>) <fpage>18</fpage>-<lpage>43</lpage>. <comment>https://doi.org/10.1016/j.ijbiomac.2020.09.204.</comment> <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.09.204</pub-id></mixed-citation></ref>
<ref id="ref26"><label>[26]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Ge</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>Y.C.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Gao</surname><given-names>S.</given-names></name></person-group> <article-title>Coupling of N7-methyltransferase and 3&#x2032;-5&#x2032; exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading</article-title>. <source>Cell</source> <volume>184</volume> (<year>2021</year>) <fpage>3474</fpage>-<lpage>3485.e3411</lpage>. <comment>https://doi.org/10.1016/j.cell.2021.05.033.</comment> <pub-id pub-id-type="doi">10.1016/j.cell.2021.05.033</pub-id></mixed-citation></ref>
<ref id="ref27"><label>[27]</label> <mixed-citation publication-type="web"><person-group person-group-type="author"><name><surname>Freer</surname><given-names>G.</given-names></name><name><surname>Lai</surname><given-names>M.</given-names></name><name><surname>Quaranta</surname><given-names>P.</given-names></name><name><surname>Spezia</surname><given-names>P.G.</given-names></name><name><surname>Pistello</surname><given-names>M.</given-names></name></person-group> <article-title>Evolution of viruses and the emergence of SARS-CoV-2 variants</article-title>. <source>New Microbiologica</source> <volume>44</volume> (<year>2021</year>) <fpage>191</fpage>-<lpage>204</lpage>. <comment><ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/europepmc.org/article/med/34942015">https://doi.org/europepmc.org/article/med/34942015</ext-link></comment>.</mixed-citation></ref>
<ref id="ref28"><label>[28]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>S.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name></person-group> <article-title>Are COVID-19 susceptibility genes related to lung cancer?</article-title> <source>Journal of Infection</source> <volume>83</volume> (<year>2021</year>) <fpage>607</fpage>-<lpage>635</lpage>. <comment>https://doi.org/10.1016/j.jinf.2021.08.032.</comment> <pub-id pub-id-type="doi">10.1016/j.jinf.2021.08.032</pub-id></mixed-citation></ref>
<ref id="ref29"><label>[29]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karthika</surname><given-names>C.</given-names></name><name><surname>Swathy Krishna</surname><given-names>R.</given-names></name><name><surname>Rahman</surname><given-names>M.</given-names></name><name><surname>Akter</surname><given-names>R.</given-names></name><name><surname>Kaushik</surname><given-names>D.</given-names></name></person-group> <article-title>COVID-19, the firestone in 21st century: a review on coronavirus disease and its clinical perspectives</article-title>. <source>Environmental Science and Pollution Research</source> <volume>28</volume> (<year>2021</year>) <fpage>64951</fpage>-<lpage>64966</lpage>. <comment>https://doi.org/10.1007/s11356-021-16654-9.</comment> <pub-id pub-id-type="doi">10.1007/s11356-021-16654-9</pub-id></mixed-citation></ref>
<ref id="ref30"><label>[30]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdecia</surname><given-names>M.</given-names></name><name><surname>Kokai-Kun</surname><given-names>J.F.</given-names></name><name><surname>Kibbey</surname><given-names>M.</given-names></name><name><surname>Acharya</surname><given-names>S.</given-names></name><name><surname>Venema</surname><given-names>J.</given-names></name><name><surname>Atouf</surname><given-names>F.</given-names></name></person-group> <article-title>COVID-19 vaccine platforms: delivering on a promise?</article-title> <source>Human Vaccines &#x0026; Immunotherapeutics</source> <volume>17</volume> (<year>2021</year>) <fpage>2873</fpage>-<lpage>2893</lpage>. <comment>https://doi.org/10.1080/21645515.2021.1911204.</comment> <pub-id pub-id-type="doi">10.1080/21645515.2021.1911204</pub-id></mixed-citation></ref>
<ref id="ref31"><label>[31]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Bi</surname><given-names>Y.</given-names></name><name><surname>Xiao</surname><given-names>H.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Duan</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group> <article-title>A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques</article-title>. <source>Emerging microbes &#x0026; infections</source> <volume>10</volume> (<year>2021</year>) <fpage>342</fpage>-<lpage>355</lpage>. <comment>https://doi.org/10.1080/22221751.2021.1887767.</comment> <pub-id pub-id-type="doi">10.1080/22221751.2021.1887767</pub-id></mixed-citation></ref>
<ref id="ref32"><label>[32]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>Y.B.</given-names></name><name><surname>Suh</surname><given-names>Y.S.</given-names></name><name><surname>Ryu</surname><given-names>J.I.</given-names></name><name><surname>Jang</surname><given-names>H.</given-names></name><name><surname>Oh</surname><given-names>H.</given-names></name><name><surname>Koo</surname><given-names>B.-S.</given-names></name><name><surname>Seo</surname><given-names>S.-H.</given-names></name><name><surname>Hong</surname><given-names>J.J.</given-names></name><name><surname>Song</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>S.-J.</given-names></name></person-group> <article-title>Soluble spike DNA vaccine provides long-term protective immunity against SARS-CoV-2 in mice and nonhuman primates</article-title>. <source>Vaccines</source> <volume>9</volume> (<year>2021</year>) <fpage>307</fpage>. <comment>https://doi.org/10.3390/vaccines9040307.</comment> <pub-id pub-id-type="doi">10.3390/vaccines9040307</pub-id></mixed-citation></ref>
<ref id="ref33"><label>[33]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doroftei</surname><given-names>B.</given-names></name><name><surname>Ciobica</surname><given-names>A.</given-names></name><name><surname>Ilie</surname><given-names>O.-D.</given-names></name><name><surname>Maftei</surname><given-names>R.</given-names></name><name><surname>Ilea</surname><given-names>C.</given-names></name></person-group> <article-title>Mini-review discussing the reliability and efficiency of COVID-19 vaccines</article-title>. <source>Diagnostics</source> <volume>11</volume> (<year>2021</year>) <fpage>579</fpage>. <comment>https://doi.org/10.3390/diagnostics11040579.</comment> <pub-id pub-id-type="doi">10.3390/diagnostics11040579</pub-id></mixed-citation></ref>
<ref id="ref34"><label>[34]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Intapiboon</surname><given-names>P.</given-names></name><name><surname>Seepathomnarong</surname><given-names>P.</given-names></name><name><surname>Ongarj</surname><given-names>J.</given-names></name><name><surname>Surasombatpattana</surname><given-names>S.</given-names></name><name><surname>Uppanisakorn</surname><given-names>S.</given-names></name><name><surname>Mahasirimongkol</surname><given-names>S.</given-names></name><name><surname>Sawaengdee</surname><given-names>W.</given-names></name><name><surname>Phumiamorn</surname><given-names>S.</given-names></name><name><surname>Sapsutthipas</surname><given-names>S.</given-names></name><name><surname>Sangsupawanich</surname><given-names>P.</given-names></name></person-group> <article-title>Immunogenicity and Safety of an Intradermal BNT162b2 mRNA vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population</article-title>. <source>Vaccines</source> <volume>9</volume> (<year>2021</year>) <fpage>1375</fpage>. <comment>https://doi.org/10.3390/vaccines9121375.</comment> <pub-id pub-id-type="doi">10.3390/vaccines9121375</pub-id></mixed-citation></ref>
<ref id="ref35"><label>[35]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>W.</given-names></name><name><surname>Gao</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>X.Q.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name></person-group> <article-title>Next&#x002D;Generation Vaccines: Nanoparticle&#x002D;Mediated DNA and mRNA Delivery</article-title>. <source>Advanced Healthcare Materials</source> <volume>10</volume> (<year>2021</year>) <fpage>2001812</fpage>. <comment>https://doi.org/10.1002/adhm.202001812.</comment> <pub-id pub-id-type="doi">10.1002/adhm.202001812</pub-id></mixed-citation></ref>
<ref id="ref36"><label>[36]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosa</surname><given-names>S.S.</given-names></name><name><surname>Prazeres</surname><given-names>D.M.</given-names></name><name><surname>Azevedo</surname><given-names>A.M.</given-names></name><name><surname>Marques</surname><given-names>M.P.</given-names></name></person-group> <article-title>mRNA vaccines manufacturing: Challenges and bottlenecks</article-title>. <source>Vaccine</source> <volume>39</volume> (<year>2021</year>) <fpage>2190</fpage>-<lpage>2200</lpage>. <comment>https://doi.org/10.1016/j.vaccine.2021.03.038.</comment> <pub-id pub-id-type="doi">10.1016/j.vaccine.2021.03.038</pub-id></mixed-citation></ref>
<ref id="ref37"><label>[37]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>R.</given-names></name><name><surname>Chaudhary</surname><given-names>J.K.</given-names></name><name><surname>Jain</surname><given-names>N.</given-names></name><name><surname>Chaudhary</surname><given-names>P.K.</given-names></name><name><surname>Khanra</surname><given-names>S.</given-names></name><name><surname>Dhamija</surname><given-names>P.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Handu</surname><given-names>S.</given-names></name></person-group> <article-title>Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19</article-title>. <source>Cells</source> <volume>10</volume> (<year>2021</year>) <fpage>821</fpage>. <comment>https://doi.org/10.3390/cells10040821.</comment> <pub-id pub-id-type="doi">10.3390/cells10040821</pub-id></mixed-citation></ref>
<ref id="ref38"><label>[38]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valdes-Balbin</surname><given-names>Y.</given-names></name><name><surname>Santana-Mederos</surname><given-names>D.</given-names></name><name><surname>Paquet</surname><given-names>F.</given-names></name><name><surname>Fernandez</surname><given-names>S.</given-names></name><name><surname>Climent</surname><given-names>Y.</given-names></name><name><surname>Chiodo</surname><given-names>F.</given-names></name><name><surname>Rodr&#x00ED;guez</surname><given-names>L.</given-names></name><name><surname>Sanchez Ramirez</surname><given-names>B.</given-names></name><name><surname>Leon</surname><given-names>K.</given-names></name><name><surname>Hernandez</surname><given-names>T.</given-names></name></person-group> <article-title>Molecular aspects concerning the use of the SARS-CoV-2 receptor binding domain as a target for preventive vaccines</article-title>. <source>ACS central science</source> <volume>7</volume> (<year>2021</year>) <fpage>757</fpage>-<lpage>767</lpage>. <comment>https://doi.org/10.1021/acscentsci.1c00216.</comment> <pub-id pub-id-type="doi">10.1021/acscentsci.1c00216</pub-id></mixed-citation></ref>
<ref id="ref39"><label>[39]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Xue</surname><given-names>W.</given-names></name><name><surname>Zheng</surname><given-names>Q.</given-names></name><name><surname>Song</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Xiong</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Hong</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name></person-group> <article-title>Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants</article-title>. <source>Nature communications</source> <volume>12</volume> (<year>2021</year>) <fpage>1</fpage>-<lpage>12</lpage>. <comment>https://doi.org/10.1038/s41467-021-25997-3.</comment> <pub-id pub-id-type="doi">10.1038/s41467-021-25997-3</pub-id></mixed-citation></ref>
<ref id="ref40"><label>[40]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Feng</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Deng</surname><given-names>Y.-Q.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Cui</surname><given-names>Z.</given-names></name><name><surname>Cao</surname><given-names>L.</given-names></name></person-group> <article-title>Structure-based development of human antibody cocktails against SARS-CoV-2</article-title>. <source>Cell Research</source> <volume>31</volume> (<year>2021</year>) <fpage>101</fpage>-<lpage>103</lpage>. <comment>https://doi.org/10.1038/s41422-020-00446-w.</comment> <pub-id pub-id-type="doi">10.1038/s41422-020-00446-w</pub-id></mixed-citation></ref>
<ref id="ref41"><label>[41]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name></person-group> <article-title>Nanoparticle-mediated cytoplasmic delivery of messenger RNA vaccines: challenges and future perspectives</article-title>. <source>Pharmaceutical Research</source> <volume>38</volume> (<year>2021</year>) <fpage>473</fpage>-<lpage>478</lpage>. <comment>https://doi.org/10.1007/s11095-021-03015-x.</comment> <pub-id pub-id-type="doi">10.1007/s11095-021-03015-x</pub-id></mixed-citation></ref>
<ref id="ref42"><label>[42]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girigoswami</surname><given-names>A.</given-names></name><name><surname>Yassine</surname><given-names>W.</given-names></name><name><surname>Sharmiladevi</surname><given-names>P.</given-names></name><name><surname>Haribabu</surname><given-names>V.</given-names></name><name><surname>Girigoswami</surname><given-names>K.</given-names></name></person-group> <article-title>Camouflaged nanosilver with excitation wavelength dependent high quantum yield for targeted theranostic</article-title>. <source>Scientific Reports</source> <volume>8</volume> (<year>2018</year>) <fpage>1</fpage>-<lpage>7</lpage>. <comment>https://doi.org/10.1038/s41598-018-34843-4.</comment> <pub-id pub-id-type="doi">10.1038/s41598-018-34843-4</pub-id></mixed-citation></ref>
<ref id="ref43"><label>[43]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haribabu</surname><given-names>V.</given-names></name><name><surname>Sharmiladevi</surname><given-names>P.</given-names></name><name><surname>Akhtar</surname><given-names>N.</given-names></name><name><surname>Farook</surname><given-names>AS</given-names></name><name><surname>Girigoswami</surname><given-names>K.</given-names></name><name><surname>Girigoswami</surname><given-names>A.</given-names></name></person-group> <article-title>Label free ultrasmall fluoromagnetic ferrite-clusters for targeted cancer imaging and drug delivery</article-title>. <source>Current Drug Delivery</source> <volume>16</volume> (<year>2019</year>) <fpage>233</fpage>-<lpage>241</lpage>. <comment>https://doi.org/10.2174/1567201816666181119112410.</comment> <pub-id pub-id-type="doi">10.2174/1567201816666181119112410</pub-id></mixed-citation></ref>
<ref id="ref44"><label>[44]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharmiladevi</surname><given-names>P.</given-names></name><name><surname>Breghatha</surname><given-names>M.</given-names></name><name><surname>Dhanavardhini</surname><given-names>K.</given-names></name><name><surname>Priya</surname><given-names>R.</given-names></name><name><surname>Girigoswami</surname><given-names>K.</given-names></name><name><surname>Girigoswami</surname><given-names>A.</given-names></name></person-group> <article-title>Efficient Wormlike Micelles for the Controlled Delivery of Anticancer Drugs</article-title>. <source>Nanoscience &#x0026; Nanotechnology-Asia</source> <volume>11</volume> (<year>2021</year>) <fpage>350</fpage>-<lpage>356</lpage>. <comment>https://doi.org/10.2174/2210681210999200728115601.</comment> <pub-id pub-id-type="doi">10.2174/2210681210999200728115601</pub-id></mixed-citation></ref>
<ref id="ref45"><label>[45]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharmiladevi</surname><given-names>P.</given-names></name><name><surname>Girigoswami</surname><given-names>K.</given-names></name><name><surname>Haribabu</surname><given-names>V.</given-names></name><name><surname>Girigoswami</surname><given-names>A.</given-names></name></person-group> <article-title>Nano-enabled theranostics for cancer</article-title>. <source>Materials Advances</source> <volume>2</volume> (<year>2021</year>) <fpage>2876</fpage>-<lpage>2891</lpage>. <comment>https://doi.org/10.1039/D1MA00069A.</comment> <pub-id pub-id-type="doi">10.1039/D1MA00069A</pub-id></mixed-citation></ref>
<ref id="ref46"><label>[46]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vedakumari</surname><given-names>S.W.</given-names></name><name><surname>Senthil</surname><given-names>R.</given-names></name><name><surname>Sekar</surname><given-names>S.</given-names></name><name><surname>Babu</surname><given-names>C.S.</given-names></name><name><surname>Sastry</surname><given-names>T.P.</given-names></name></person-group> <article-title>Enhancing anti-cancer activity of erlotinib by antibody conjugated nanofibrin-in vitro studies on lung adenocarcinoma cell lines</article-title>. <source>Materials Chemistry and Physics</source> <volume>224</volume> (<year>2019</year>) <fpage>328</fpage>-<lpage>333</lpage>. <comment>https://doi.org/10.1016/j.matchemphys.2018.11.061.</comment> <pub-id pub-id-type="doi">10.1016/j.matchemphys.2018.11.061</pub-id></mixed-citation></ref>
<ref id="ref47"><label>[47]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazer</surname><given-names>LM</given-names></name><name><surname>Sadhasivam</surname><given-names>B.</given-names></name><name><surname>Palaniyandi</surname><given-names>K.</given-names></name><name><surname>Muthuswamy</surname><given-names>T.</given-names></name><name><surname>Ramachandran</surname><given-names>I.</given-names></name><name><surname>Balakrishnan</surname><given-names>A.</given-names></name><name><surname>Pathak</surname><given-names>S.</given-names></name><name><surname>Narayan</surname><given-names>S.</given-names></name><name><surname>Ramalingam</surname><given-names>S.</given-names></name></person-group> <article-title>Chitosan-based nano-formulation enhances the anticancer efficacy of hesperetin</article-title>. <source>International Journal of Biological Macromolecules</source> <volume>107</volume> (<year>2018</year>) <fpage>1988</fpage>-<lpage>1998</lpage>. <comment>https://doi.org/10.1016/j.ijbiomac.2017.10.064.</comment> <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2017.10.064</pub-id></mixed-citation></ref>
<ref id="ref48"><label>[48]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>F.</given-names></name><name><surname>Teng</surname><given-names>Z.</given-names></name><name><surname>Ru</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Guo</surname><given-names>H.</given-names></name></person-group> <article-title>Flower-like mesoporous silica nanoparticles as an antigen delivery platform to promote systemic immune response</article-title>. <source>Nanomedicine: Nanotechnology, Biology and Medicine</source> <volume>42</volume> (<year>2022</year>) <fpage>102541</fpage>. <comment>https://doi.org/10.1016/j.nano.2022.102541.</comment> <pub-id pub-id-type="doi">10.1016/j.nano.2022.102541</pub-id></mixed-citation></ref>
<ref id="ref49"><label>[49]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perciani</surname><given-names>C.T.</given-names></name><name><surname>Liu</surname><given-names>L.Y.</given-names></name><name><surname>Wood</surname><given-names>L.</given-names></name><name><surname>MacParland</surname><given-names>S.A.</given-names></name></person-group> <article-title>Enhancing immunity with nanomedicine: Employing nanoparticles to harness the immune system</article-title>. <source>ACS nano</source> <volume>15</volume> (<year>2020</year>) <fpage>7</fpage>-<lpage>20</lpage>. <comment>https://doi.org/10.1021/acsnano.0c08913.</comment> <pub-id pub-id-type="doi">10.1021/acsnano.0c08913</pub-id></mixed-citation></ref>
<ref id="ref50"><label>[50]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenmaker</surname><given-names>L.</given-names></name><name><surname>Witzigmann</surname><given-names>D.</given-names></name><name><surname>Kulkarni</surname><given-names>J.A.</given-names></name><name><surname>Verbeke</surname><given-names>R.</given-names></name><name><surname>Kersten</surname><given-names>G.</given-names></name><name><surname>Jiskoot</surname><given-names>W.</given-names></name><name><surname>Crommelin</surname><given-names>D.J.</given-names></name></person-group> <article-title>mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability</article-title>. <source>International Journal of Pharmaceutics</source> <volume>601</volume> (<year>2021</year>) <fpage>120586</fpage>. <comment>https://doi.org/10.1016/j.ijpharm.2021.120586.</comment> <pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120586</pub-id></mixed-citation></ref>
<ref id="ref51"><label>[51]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Praet</surname><given-names>J.</given-names></name><name><surname>Reynders</surname><given-names>M.</given-names></name><name><surname>De Bacquer</surname><given-names>D.</given-names></name><name><surname>Viaene</surname><given-names>L.</given-names></name><name><surname>Schoutteten</surname><given-names>M.K.</given-names></name><name><surname>Caluw&#x00E9;</surname><given-names>R.</given-names></name><name><surname>Doubel</surname><given-names>P.</given-names></name><name><surname>Heylen</surname><given-names>L.</given-names></name><name><surname>De Bel</surname><given-names>A.V.</given-names></name><name><surname>Van Vlem</surname><given-names>B.</given-names></name></person-group> <article-title>Predictors and dynamics of the humoral and cellular immune response to SARS-CoV-2 mRNA vaccines in hemodialysis patients: a multicenter observational study</article-title>. <source>Journal of the American Society of Nephrology</source> <volume>32</volume> (<year>2021</year>) <fpage>3208</fpage>-<lpage>3220</lpage>. <comment>https://doi.org/10.1681/ASN.2021070908.</comment> <pub-id pub-id-type="doi">10.1681/ASN.2021070908</pub-id></mixed-citation></ref>
<ref id="ref52"><label>[52]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamidi-Asl</surname><given-names>E.</given-names></name><name><surname>Heidari</surname><given-names>L.</given-names></name><name><surname>Raoof</surname><given-names>J.B.</given-names></name><name><surname>Richard</surname><given-names>T.P.</given-names></name><name><surname>Farhad</surname><given-names>S.</given-names></name><name><surname>Ghani</surname><given-names>M.</given-names></name></person-group> <article-title>A review on the recent achievements on coronaviruses recognition using electrochemical detection methods</article-title>. <source>Microchemical Journal</source> (<year>2022</year>) <fpage>107322</fpage>. <comment>https://doi.org/10.1016/j.microc.2022.107322.</comment> <pub-id pub-id-type="doi">10.1016/j.microc.2022.107322</pub-id></mixed-citation></ref>
<ref id="ref53"><label>[53]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priyanka</surname><given-names>C.O.</given-names></name><name><surname>Singh</surname><given-names>I.</given-names></name></person-group> <article-title>Diagnosis of SARS-CoV-2: a review on the current scenario and future outlook</article-title>. <source>Acta Virologica</source> <volume>64</volume> (<year>2020</year>) <fpage>396</fpage>-<lpage>408</lpage>. <comment>https://doi.org/10.4149/av_2020_402.</comment> <pub-id pub-id-type="doi">10.4149/av_2020_402</pub-id></mixed-citation></ref>
<ref id="ref54"><label>[54]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>S.</given-names></name><name><surname>Sadique</surname><given-names>M.A.</given-names></name><name><surname>Ranjan</surname><given-names>P.</given-names></name><name><surname>Kumar</surname><given-names>N.</given-names></name><name><surname>Singhal</surname><given-names>A.</given-names></name><name><surname>Srivastava</surname><given-names>A.K.</given-names></name><name><surname>Khan</surname><given-names>R.</given-names></name></person-group> <article-title>SERS based lateral flow immunoassay for point-of-care detection of SARS-CoV-2 in clinical samples</article-title>. <source>ACS Applied Bio Materials</source> <volume>4</volume> (<year>2021</year>) <fpage>2974</fpage>-<lpage>2995</lpage>. <comment>https://doi.org/10.1021/acsabm.1c00102.</comment> <pub-id pub-id-type="doi">10.1021/acsabm.1c00102</pub-id></mixed-citation></ref>
<ref id="ref55"><label>[55]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>D.</given-names></name><name><surname>Lei</surname><given-names>Y.</given-names></name></person-group> <article-title>Mini review: Recent progress in RT-LAMP enabled COVID-19 detection</article-title>. <source>Sensors and Actuators Reports</source> <volume>2</volume> (<year>2020</year>) <fpage>100017</fpage>. <comment>https://doi.org/10.1016/j.snr.2020.100017.</comment> <pub-id pub-id-type="doi">10.1016/j.snr.2020.100017</pub-id></mixed-citation></ref>
<ref id="ref56"><label>[56]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukose</surname><given-names>J.</given-names></name><name><surname>Chidangil</surname><given-names>S.</given-names></name><name><surname>George</surname><given-names>S.D.</given-names></name></person-group> <article-title>Optical technologies for the detection of viruses like COVID-19: Progress and prospects</article-title>. <source>Biosensors and Bioelectronics</source> <volume>178</volume> (<year>2021</year>) <fpage>113004</fpage>. <comment>https://doi.org/10.1016/j.bios.2021.113004.</comment> <pub-id pub-id-type="doi">10.1016/j.bios.2021.113004</pub-id></mixed-citation></ref>
<ref id="ref57"><label>[57]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Liang</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name></person-group> <article-title>Enzyme-antibody-modified gold nanoparticle probes for the ultrasensitive detection of nucleocapsid protein in SFTSV</article-title>. <source>International Journal of Environmental Research and Public Health</source> <volume>17</volume> (<year>2020</year>) <fpage>4427</fpage>. <comment>https://doi.org/10.3390/ijerph17124427.</comment> <pub-id pub-id-type="doi">10.3390/ijerph17124427</pub-id></mixed-citation></ref>
<ref id="ref58"><label>[58]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>H.K.</given-names></name><name><surname>Lee</surname><given-names>M.-J.</given-names></name><name><surname>Lee</surname><given-names>S.N.</given-names></name><name><surname>Kim</surname><given-names>T.-H.</given-names></name><name><surname>Oh</surname><given-names>B.-K.</given-names></name></person-group> <article-title>Noble metal nanomaterial-based biosensors for electrochemical and optical detection of viruses causing respiratory illnesses</article-title>. <source>Frontiers in Chemistry</source> <volume>9</volume> (<year>2021</year>). <comment>https://doi.org/10.3389/fchem.2021.672739.</comment> <pub-id pub-id-type="doi">10.3389/fchem.2021.672739</pub-id></mixed-citation></ref>
<ref id="ref59"><label>[59]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Girigoswami</surname><given-names>K.</given-names></name><name><surname>Girigoswami</surname><given-names>A.</given-names></name></person-group> <article-title>Membrane-encapsulated camouflaged nanomedicines in drug delivery</article-title>. <source>Nanomedicine: Nanotechnology, Biology, and Medicine</source> <volume>14</volume> (<year>2019</year>) <fpage>2067</fpage>-<lpage>2082</lpage>. <comment>https://doi.org/10.2217/nnm-2019-0155.</comment> <pub-id pub-id-type="doi">10.2217/nnm-2019-0155</pub-id></mixed-citation></ref>
<ref id="ref60"><label>[60]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haribabu</surname><given-names>V.</given-names></name><name><surname>Girigoswami</surname><given-names>K.</given-names></name><name><surname>Girigoswami</surname><given-names>A.</given-names></name></person-group> <article-title>Magneto-silver core&#x2013;shell nanohybrids for theragnosis</article-title>. <source>Nano-Structures &#x0026; Nano-Objects</source> <volume>25</volume> (<year>2021</year>) <fpage>100636</fpage>. <comment>https://doi.org/10.1016/j.nanoso.2020.100636.</comment> <pub-id pub-id-type="doi">10.1016/j.nanoso.2020.100636</pub-id></mixed-citation></ref>
<ref id="ref61"><label>[61]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agraharam</surname><given-names>G.</given-names></name><name><surname>Girigoswami</surname><given-names>A.</given-names></name><name><surname>Girigoswami</surname><given-names>K.</given-names></name></person-group> <article-title>Nanoencapsulated Myricetin to Improve Antioxidant Activity and Bioavailability: A Study on Zebrafish Embryos</article-title>. <source>Chemistry</source> <volume>4</volume> (<year>2021</year>) <fpage>1</fpage>-<lpage>17</lpage>. <comment>https://doi.org/10.3390/chemistry4010001.</comment> <pub-id pub-id-type="doi">10.3390/chemistry4010001</pub-id></mixed-citation></ref>
<ref id="ref62"><label>[62]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medhi</surname><given-names>R.</given-names></name><name><surname>Srinoi</surname><given-names>P.</given-names></name><name><surname>Ngo</surname><given-names>N.</given-names></name><name><surname>Tran</surname><given-names>H.-V.</given-names></name><name><surname>Lee</surname><given-names>T.R.</given-names></name></person-group> <article-title>Nanoparticle-based strategies to combat COVID-19</article-title>. <source>ACS Applied Nano Materials</source> <volume>3</volume> (<year>2020</year>) <fpage>8557</fpage>-<lpage>8580</lpage>. <comment>https://doi.org/10.1021/acsanm.0c01978.</comment> <pub-id pub-id-type="doi">10.1021/acsanm.0c01978</pub-id></mixed-citation></ref>
<ref id="ref63"><label>[63]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durmus</surname><given-names>C.</given-names></name><name><surname>Hanoglu</surname><given-names>S.B.</given-names></name><name><surname>Harmanci</surname><given-names>D.</given-names></name><name><surname>Moulahoum</surname><given-names>H.</given-names></name><name><surname>Tok</surname><given-names>K.</given-names></name><name><surname>Ghorbanizamani</surname><given-names>F.</given-names></name><name><surname>Sanli</surname><given-names>S.</given-names></name><name><surname>Zihnioglu</surname><given-names>F.</given-names></name><name><surname>Evran</surname><given-names>S.</given-names></name><name><surname>Cicek</surname><given-names>C.</given-names></name></person-group> <article-title>Indiscriminate SARS-CoV-2 multivariant detection using magnetic nanoparticle-based electrochemical immunosensing</article-title>. <source>Talanta</source> (<year>2022</year>) <fpage>123356</fpage>. <comment>https://doi.org/10.1016/j.talanta.2022.123356.</comment> <pub-id pub-id-type="doi">10.1016/j.talanta.2022.123356</pub-id></mixed-citation></ref>
<ref id="ref64"><label>[64]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dube</surname><given-names>T.</given-names></name><name><surname>Ghosh</surname><given-names>A.</given-names></name><name><surname>Mishra</surname><given-names>J.</given-names></name><name><surname>Kompella</surname><given-names>U.B.</given-names></name><name><surname>Panda</surname><given-names>J.J.</given-names></name></person-group> <article-title>Repurposed drugs, molecular vaccines, immune&#x002D;modulators, and nanotherapeutics to treat and prevent COVID&#x002D;19 associated with SARS&#x002D;CoV&#x002D;2, a deadly nanovector</article-title>. <source>Advanced therapeutics</source> <volume>4</volume> (<year>2021</year>) <fpage>2000172</fpage>. <comment>https://doi.org/10.1002/adtp.202000172.</comment> <pub-id pub-id-type="doi">10.1002/adtp.202000172</pub-id></mixed-citation></ref>
<ref id="ref65"><label>[65]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouffak</surname><given-names>S.</given-names></name><name><surname>Shubbar</surname><given-names>Q.</given-names></name><name><surname>Saleh</surname><given-names>E.</given-names></name><name><surname>El-Awady</surname><given-names>R.</given-names></name></person-group> <article-title>Recent advances in management of COVID-19: a review</article-title>. <source>Biomedicine and Pharmacotherapy</source> <volume>143</volume> (<year>2021</year>) <fpage>112107</fpage>. <comment>https://doi.org/10.1016/j.biopha.2021.112107.</comment> <pub-id pub-id-type="doi">10.1016/j.biopha.2021.112107</pub-id></mixed-citation></ref>
<ref id="ref66"><label>[66]</label> <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Girigoswami</surname><given-names>K.</given-names></name><name><surname>Pallavi</surname><given-names>P.</given-names></name><name><surname>Girigoswami</surname><given-names>A.</given-names></name></person-group>, <source>Targeting Cancer Stem Cells by Nanoenabled Drug Delivery, in Cancer Stem Cells: New Horizons in Cancer Therapies</source>, <publisher-name>Springer</publisher-name> <year>2020</year>, p. <fpage>313</fpage>-<lpage>337</lpage>. <comment>https://doi.org/10.1007/978-981-15-5120-8_17.</comment> <pub-id pub-id-type="doi">10.1007/978-981-15-5120-8_17</pub-id></mixed-citation></ref>
<ref id="ref67"><label>[67]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vimaladevi</surname><given-names>M.</given-names></name><name><surname>Divya</surname><given-names>K.C.</given-names></name><name><surname>Girigoswami</surname><given-names>A.</given-names></name></person-group> <article-title>Liposomal nanoformulations of rhodamine for targeted photodynamic inactivation of multidrug resistant gram negative bacteria in sewage treatment plant</article-title>. <source>Journal of Photochemistry and Photobiology B: Biology</source> <volume>162</volume> (<year>2016</year>) <fpage>146</fpage>-<lpage>152</lpage>. <comment>https://doi.org/10.1016/j.jphotobiol.2016.06.034.</comment> <pub-id pub-id-type="doi">10.1016/j.jphotobiol.2016.06.034</pub-id></mixed-citation></ref>
<ref id="ref68"><label>[68]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chekulayeva</surname><given-names>L.V.</given-names></name><name><surname>Shevchuk</surname><given-names>I.N.</given-names></name><name><surname>Chekulayev</surname><given-names>V.A.</given-names></name><name><surname>Ilmarinen</surname><given-names>K.</given-names></name></person-group> <article-title>Hydrogen peroxide, superoxide, and hydroxyl radicals are involved in the phototoxic action of hematoporphyrin derivative against tumor cells</article-title>. <source>Journal of Environmental Pathology, Toxicology and Oncology</source> <volume>25</volume> (<year>2006</year>). <comment>https://doi.org/10.1615/JEnvironPatholToxicolOncol.v25.i1-2.40.</comment> <pub-id pub-id-type="doi">10.1615/JEnvironPatholToxicolOncol.v25.i1-2.40</pub-id></mixed-citation></ref>
<ref id="ref69"><label>[69]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>M.</given-names></name><name><surname>Reiners</surname><given-names>J.J.</given-names></name><name><surname>Santiago</surname><given-names>A.M.</given-names></name><name><surname>Kessel</surname><given-names>D.</given-names></name></person-group> <article-title>Monitoring singlet oxygen and hydroxyl radical formation with fluorescent probes during photodynamic therapy</article-title>. <source>Photochemistry and Photobiology</source> <volume>85</volume> (<year>2009</year>) <fpage>1177</fpage>-<lpage>1181</lpage>. <comment>https://doi.org/10.1111/j.1751-1097.2009.00555.x.</comment> <pub-id pub-id-type="doi">10.1111/j.1751-1097.2009.00555.x</pub-id></mixed-citation></ref>
<ref id="ref70"><label>[70]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibu</surname><given-names>E.S.</given-names></name><name><surname>Hamada</surname><given-names>M.</given-names></name><name><surname>Murase</surname><given-names>N.</given-names></name><name><surname>Biju</surname><given-names>V.</given-names></name></person-group> <article-title>Nanomaterials formulations for photothermal and photodynamic therapy of cancer</article-title>. <source>Journal of Photochemistry and Photobiology C: Photochemistry Reviews</source> <volume>15</volume> (<year>2013</year>) <fpage>53</fpage>-<lpage>72</lpage>. <comment>https://doi.org/10.1016/j.jphotochemrev.2012.09.004.</comment> <pub-id pub-id-type="doi">10.1016/j.jphotochemrev.2012.09.004</pub-id></mixed-citation></ref>
<ref id="ref71"><label>[71]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castano</surname><given-names>A.P.</given-names></name><name><surname>Demidova</surname><given-names>T.N.</given-names></name><name><surname>Hamblin</surname><given-names>M.R.</given-names></name></person-group> <article-title>Mechanisms in photodynamic therapy: part three&#x2014;photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction</article-title>. <source>Photodiagnosis and Photodynamic Therapy</source> <volume>2</volume> (<year>2005</year>) <fpage>91</fpage>-<lpage>106</lpage>. <comment>https://doi.org/10.1016/S1572-1000(05)00060-8.</comment> <pub-id pub-id-type="doi">10.1016/S1572-1000(05)00060-8</pub-id></mixed-citation></ref>
<ref id="ref72"><label>[72]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x0105;browski</surname><given-names>J.M.</given-names></name><name><surname>Arnaut</surname><given-names>L.G.</given-names></name></person-group> <article-title>Photodynamic therapy (PDT) of cancer: from local to systemic treatment</article-title>. <source>Photochemical &#x0026; Photobiological Sciences</source> <volume>14</volume> (<year>2015</year>) <fpage>1765</fpage>-<lpage>1780</lpage>. <comment>https://doi.org/10.1039/C5PP00132C.</comment> <pub-id pub-id-type="doi">10.1039/C5PP00132C</pub-id></mixed-citation></ref>
<ref id="ref73"><label>[73]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hillemanns</surname><given-names>P.</given-names></name><name><surname>Einstein</surname><given-names>M.H.</given-names></name><name><surname>Iversen</surname><given-names>O.E.</given-names></name></person-group> <article-title>Topical hexaminolevulinate photodynamic therapy for the treatment of persistent human papilloma virus infections and cervical intraepithelial neoplasia</article-title>. <source>Expert Opinion on Investigational Drugs</source> <volume>24</volume> (<year>2015</year>) <fpage>273</fpage>-<lpage>281</lpage>. <comment>https://doi.org/10.1517/13543784.2015.990150.</comment> <pub-id pub-id-type="doi">10.1517/13543784.2015.990150</pub-id></mixed-citation></ref>
<ref id="ref74"><label>[74]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dias</surname><given-names>LD.</given-names></name><name><surname>Bagnato</surname><given-names>V.S.</given-names></name></person-group> <article-title>An update on clinical photodynamic therapy for fighting respiratory tract infections: a promising tool against COVID-19 and its co-infections</article-title>. <source>Laser Physics Letters</source> <volume>17</volume> (<year>2020</year>) <fpage>083001</fpage>. <comment>https://doi.org/10.1088/1612-202X/ab95a9.</comment> <pub-id pub-id-type="doi">10.1088/1612-202X/ab95a9</pub-id></mixed-citation></ref>
<ref id="ref75"><label>[75]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svyatchenko</surname><given-names>V.A.</given-names></name><name><surname>Nikonov</surname><given-names>S.D.</given-names></name><name><surname>Mayorov</surname><given-names>A.P.</given-names></name><name><surname>Gelfond</surname><given-names>M.L.</given-names></name><name><surname>Loktev</surname><given-names>V.B.</given-names></name></person-group> <article-title>Antiviral photodynamic therapy: Inactivation and inhibition of SARS-CoV-2 in vitro using methylene blue and Radachlorin</article-title>. <source>Photodiagnosis and Photodynamic Therapy</source> <volume>33</volume> (<year>2021</year>) <fpage>102112</fpage>. <comment>https://doi.org/10.1016/j.pdpdt.2020.102112.</comment> <pub-id pub-id-type="doi">10.1016/j.pdpdt.2020.102112</pub-id></mixed-citation></ref>
<ref id="ref76"><label>[76]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khorsandi</surname><given-names>K.</given-names></name><name><surname>Fekrazad</surname><given-names>S.</given-names></name><name><surname>Vahdatinia</surname><given-names>F.</given-names></name><name><surname>Farmany</surname><given-names>A.</given-names></name><name><surname>Fekrazad</surname><given-names>R.</given-names></name></person-group> <article-title>Nano antiviral photodynamic therapy: A probable biophysicochemical management modality in SARS-CoV-2</article-title>. <source>Expert Opinion on Drug Delivery</source> <volume>18</volume> (<year>2021</year>) <fpage>265</fpage>-<lpage>272</lpage>. <comment>https://doi.org/10.1080/17425247.2021.1829591.</comment> <pub-id pub-id-type="doi">10.1080/17425247.2021.1829591</pub-id></mixed-citation></ref>
<ref id="ref77"><label>[77]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabino</surname><given-names>C.P.</given-names></name><name><surname>Ball</surname><given-names>A.R.</given-names></name><name><surname>Baptista</surname><given-names>M.S.</given-names></name><name><surname>Dai</surname><given-names>T.</given-names></name><name><surname>Hamblin</surname><given-names>M.R.</given-names></name><name><surname>Ribeiro</surname><given-names>M.S.</given-names></name><name><surname>Santos</surname><given-names>A.L.</given-names></name><name><surname>Sellera</surname><given-names>F.P.</given-names></name><name><surname>Tegos</surname><given-names>G.P.</given-names></name><name><surname>Wainwright</surname><given-names>M.</given-names></name></person-group> <article-title>Light-based technologies for management of COVID-19 pandemic crisis</article-title>. <source>Journal of Photochemistry and Photobiology B: Biology</source> <volume>212</volume> (<year>2020</year>) <fpage>111999</fpage>. <comment>https://doi.org/10.1016/j.jphotobiol.2020.111999.</comment> <pub-id pub-id-type="doi">10.1016/j.jphotobiol.2020.111999</pub-id></mixed-citation></ref>
<ref id="ref78"><label>[78]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmoudi</surname><given-names>H.</given-names></name><name><surname>Bahador</surname><given-names>A.</given-names></name><name><surname>Pourhajibagher</surname><given-names>M.</given-names></name><name><surname>Alikhani</surname><given-names>M.Y.</given-names></name></person-group> <article-title>Antimicrobial photodynamic therapy: an effective alternative approach to control bacterial infections</article-title>. <source>Journal of lasers in medical sciences</source> <volume>9</volume> (<year>2018</year>) <fpage>154</fpage>. <comment>https://doi.org/10.15171/jlms.2018.29.</comment> <pub-id pub-id-type="doi">10.15171/jlms.2018.29</pub-id></mixed-citation></ref>
<ref id="ref79"><label>[79]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gheblawi</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Viveiros</surname><given-names>A.</given-names></name><name><surname>Nguyen</surname><given-names>Q.</given-names></name><name><surname>Zhong</surname><given-names>J.-C.</given-names></name><name><surname>Turner</surname><given-names>A.J.</given-names></name><name><surname>Raizada</surname><given-names>M.K.</given-names></name><name><surname>Grant</surname><given-names>M.B.</given-names></name><name><surname>Oudit</surname><given-names>G.Y.</given-names></name></person-group> <article-title>Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2</article-title>. <source>Circulation Research</source> <volume>126</volume> (<year>2020</year>) <fpage>1456</fpage>-<lpage>1474</lpage>. <comment>https://doi.org/10.1161/CIRCRESAHA.120.317015.</comment> <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.317015</pub-id></mixed-citation></ref>
<ref id="ref80"><label>[80]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klausen</surname><given-names>M.</given-names></name><name><surname>Ucuncu</surname><given-names>M.</given-names></name><name><surname>Bradley</surname><given-names>M.</given-names></name></person-group> <article-title>Design of photosensitizing agents for targeted antimicrobial photodynamic therapy</article-title>. <source>Molecules</source> <volume>25</volume> (<year>2020</year>) <fpage>5239</fpage>. <comment>https://doi.org/10.3390/molecules25225239.</comment> <pub-id pub-id-type="doi">10.3390/molecules25225239</pub-id></mixed-citation></ref>
<ref id="ref81"><label>[81]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sansaloni-Pastor</surname><given-names>S.</given-names></name><name><surname>Bouilloux</surname><given-names>J.</given-names></name><name><surname>Lange</surname><given-names>N.</given-names></name></person-group> <article-title>The dark side: photosensitizer prodrugs</article-title>. <source>Pharmaceuticals</source> <volume>12</volume> (<year>2019</year>) <fpage>148</fpage>. <comment>https://doi.org/10.3390/ph12040148.</comment> <pub-id pub-id-type="doi">10.3390/ph12040148</pub-id></mixed-citation></ref>
<ref id="ref82"><label>[82]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swamy</surname><given-names>P.C.A.</given-names></name><name><surname>Sivaraman</surname><given-names>G.</given-names></name><name><surname>Priyanka</surname><given-names>R.N.</given-names></name><name><surname>Raja</surname><given-names>S.O.</given-names></name><name><surname>Ponnuvel</surname><given-names>K.</given-names></name><name><surname>Shanmugpriya</surname><given-names>J.</given-names></name><name><surname>Gulyani</surname><given-names>A.</given-names></name></person-group> <article-title>Near Infrared (NIR) absorbing dyes as promising photosensitizer for photo dynamic therapy</article-title>. <source>Coordination Chemistry Reviews</source> <volume>411</volume> (<year>2020</year>) <fpage>213233</fpage>. <comment>https://doi.org/10.1016/j.ccr.2020.213233.</comment> <pub-id pub-id-type="doi">10.1016/j.ccr.2020.213233</pub-id></mixed-citation></ref>
<ref id="ref83"><label>[83]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mavridi-Printezi</surname><given-names>A.</given-names></name><name><surname>Guernelli</surname><given-names>M.</given-names></name><name><surname>Menichetti</surname><given-names>A.</given-names></name><name><surname>Montalti</surname><given-names>M.</given-names></name></person-group> <article-title>Bio-Applications of Multifunctional Melanin Nanoparticles: From Nanomedicine to Nanocosmetics</article-title>. <source>Nanomaterials</source> <volume>10</volume> (<year>2020</year>) <fpage>2276</fpage>. <comment>https://doi.org/10.3390/nano10112276.</comment> <pub-id pub-id-type="doi">10.3390/nano10112276</pub-id></mixed-citation></ref>
<ref id="ref84"><label>[84]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>M.E.</given-names></name><name><surname>Lee</surname><given-names>Y.-l.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Chu</surname><given-names>J.J.H.</given-names></name></person-group> <article-title>Photodynamic inactivation of viruses using upconversion nanoparticles</article-title>. <source>Biomaterials</source> <volume>33</volume> (<year>2012</year>) <fpage>1912</fpage>-<lpage>1920</lpage>. <comment>https://doi.org/10.1016/j.biomaterials.2011.11.033.</comment> <pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.11.033</pub-id></mixed-citation></ref>
<ref id="ref85"><label>[85]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youf</surname><given-names>R.</given-names></name><name><surname>M&#x00FC;ller</surname><given-names>M.</given-names></name><name><surname>Balasini</surname><given-names>A.</given-names></name><name><surname>Th&#x00E9;tiot</surname><given-names>F.</given-names></name><name><surname>M&#x00FC;ller</surname><given-names>M.</given-names></name><name><surname>Hasco&#x00EB;t</surname><given-names>A.</given-names></name><name><surname>Jonas</surname><given-names>U.</given-names></name><name><surname>Sch&#x00F6;nherr</surname><given-names>H.</given-names></name><name><surname>Lemercier</surname><given-names>G.</given-names></name><name><surname>Montier</surname><given-names>T.</given-names></name></person-group> <article-title>Antimicrobial photodynamic therapy: Latest developments with a focus on combinatory strategies</article-title>. <source>Pharmaceutics</source> <volume>13</volume> (<year>2021</year>) <fpage>1995</fpage>. <comment>https://doi.org/10.3390/pharmaceutics13121995.</comment> <pub-id pub-id-type="doi">10.3390/pharmaceutics13121995</pub-id></mixed-citation></ref>
<ref id="ref86"><label>[86]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>I.</given-names></name><name><surname>Douaisi</surname><given-names>M.P.</given-names></name><name><surname>Mondal</surname><given-names>D.</given-names></name><name><surname>Kane</surname><given-names>R.S.</given-names></name></person-group> <article-title>Light-activated nanotube&#x2013;porphyrin conjugates as effective antiviral agents</article-title>. <source>Nanotechnology</source> <volume>23</volume> (<year>2012</year>) <fpage>105101</fpage>. <comment>https://doi.org/10.1088/0957-4484/23/10/105101.</comment> <pub-id pub-id-type="doi">10.1088/0957-4484/23/10/105101</pub-id></mixed-citation></ref>
<ref id="ref87"><label>[87]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nascimento</surname><given-names>I.J.d.S.</given-names></name><name><surname>de Aquino</surname><given-names>T.M.</given-names></name><name><surname>da Silva-J&#x00FA;nior</surname><given-names>E.F.</given-names></name></person-group> <article-title>The new era of drug discovery: The power of computer-aided drug design (CADD)</article-title>. <source>Letters in Drug Design &#x0026; Discovery</source> <volume>19</volume> (<year>2022</year>) <fpage>951</fpage>-<lpage>955</lpage>. <comment>https://doi.org/10.2174/1570180819666220405225817.</comment> <pub-id pub-id-type="doi">10.2174/1570180819666220405225817</pub-id></mixed-citation></ref>
<ref id="ref88"><label>[88]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Sun</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Jiang</surname><given-names>Q.</given-names></name><name><surname>He</surname><given-names>Z.</given-names></name><name><surname>Ding</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name></person-group> <article-title>A computer-aided chem-photodynamic drugs self-delivery system for synergistically enhanced cancer therapy</article-title>. <source>Asian Journal of Pharmaceutical Sciences</source> <volume>16</volume> (<year>2021</year>) <fpage>203</fpage>-<lpage>212</lpage>. <comment>https://doi.org/10.1016/j.ajps.2020.04.002.</comment> <pub-id pub-id-type="doi">10.1016/j.ajps.2020.04.002</pub-id></mixed-citation></ref>
<ref id="ref89"><label>[89]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedorov</surname><given-names>V.</given-names></name><name><surname>Kholina</surname><given-names>E.</given-names></name><name><surname>Khruschev</surname><given-names>S.</given-names></name><name><surname>Kovalenko</surname><given-names>I.</given-names></name><name><surname>Rubin</surname><given-names>A.</given-names></name><name><surname>Strakhovskaya</surname><given-names>M.</given-names></name></person-group> <article-title>Electrostatic map of the SARS-CoV-2 virion specifies binding sites of the antiviral cationic photosensitizer</article-title>. <source>International Journal of Molecular Sciences</source> <volume>23</volume> (<year>2022</year>) <fpage>7304</fpage>. <comment>https://doi.org/10.3390/ijms23137304.</comment> <pub-id pub-id-type="doi">10.3390/ijms23137304</pub-id></mixed-citation></ref>
<ref id="ref90"><label>[90]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharshov</surname><given-names>K.</given-names></name><name><surname>Solomatina</surname><given-names>M.</given-names></name><name><surname>Kurskaya</surname><given-names>O.</given-names></name><name><surname>Kovalenko</surname><given-names>I.</given-names></name><name><surname>Kholina</surname><given-names>E.</given-names></name><name><surname>Fedorov</surname><given-names>V.</given-names></name><name><surname>Meerovich</surname><given-names>G.</given-names></name><name><surname>Rubin</surname><given-names>A.</given-names></name><name><surname>Strakhovskaya</surname><given-names>M.</given-names></name></person-group> <article-title>The photosensitizer octakis (cholinyl) zinc phthalocyanine with ability to bind to a model spike protein leads to a loss of SARS-CoV-2 infectivity in vitro when exposed to far-red LED</article-title>. <source>Viruses</source> <volume>13</volume> (<year>2021</year>) <fpage>643</fpage>. <comment>https://doi.org/10.3390/v13040643.</comment> <pub-id pub-id-type="doi">10.3390/v13040643</pub-id></mixed-citation></ref>
<ref id="ref91"><label>[91]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>W.-B.</given-names></name><name><surname>Sun</surname><given-names>F.-Y.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>J.-F.</given-names></name><name><surname>Hao</surname><given-names>X.-L.</given-names></name><name><surname>Ren</surname><given-names>A.-M.</given-names></name></person-group> <article-title>Photophysical properties of Pt (II) and Pd (II) complexes for two-photon photodynamic therapy: A computational investigation</article-title>. <source>Dyes and Pigments</source> <volume>215</volume> (<year>2023</year>) <fpage>111283</fpage>. <comment>https://doi.org/10.1016/j.dyepig.2023.111283.</comment> <pub-id pub-id-type="doi">10.1016/j.dyepig.2023.111283</pub-id></mixed-citation></ref>
<ref id="ref92"><label>[92]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>J.</given-names></name><name><surname>Kang</surname><given-names>D.W.</given-names></name><name><surname>Lim</surname><given-names>J.H.</given-names></name><name><surname>An</surname><given-names>J.M.</given-names></name><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Ji</surname><given-names>M.S.</given-names></name><name><surname>Park</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Lee</surname><given-names>J.Y.</given-names></name></person-group> <article-title>Wavelength engineerable porous organic polymer photosensitizers with protonation triggered ROS generation</article-title>. <source>Nature communications</source> <volume>14</volume> (<year>2023</year>) <fpage>1498</fpage>. <comment>https://doi.org/10.1038/s41467-023-37156-x.</comment> <pub-id pub-id-type="doi">10.1038/s41467-023-37156-x</pub-id></mixed-citation></ref>
<ref id="ref93"><label>[93]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kundu</surname><given-names>BK.</given-names></name><name><surname>Han</surname><given-names>G.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name></person-group> <article-title>Derivatized benzothiazoles as two-photon-absorbing organic photosensitizers active under near infrared light irradiation</article-title>. <source>Journal of the American Chemical Society</source> <volume>145</volume> (<year>2023</year>) <fpage>3535</fpage>-<lpage>3542</lpage>. <comment>https://doi.org/10.1021/jacs.2c12244.</comment> <pub-id pub-id-type="doi">10.1021/jacs.2c12244</pub-id></mixed-citation></ref>
<ref id="ref94"><label>[94]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prieto-Montero</surname><given-names>R.</given-names></name><name><surname>Andres</surname><given-names>A.D.</given-names></name><name><surname>Prieto-Casta&#x00F1;eda</surname><given-names>A.</given-names></name><name><surname>Tabero</surname><given-names>A.</given-names></name><name><surname>Longarte</surname><given-names>A.</given-names></name><name><surname>Agarrabeitia</surname><given-names>A.R.</given-names></name><name><surname>Villanueva</surname><given-names>A.</given-names></name><name><surname>Ortiz</surname><given-names>M.J.</given-names></name><name><surname>Montero</surname><given-names>R.</given-names></name><name><surname>Casanova</surname><given-names>D.</given-names></name></person-group> <article-title>Halogen-free photosensitizers based on meso-enamine-BODIPYs for bioimaging and photodynamic therapy</article-title>. <source>Journal of Materials Chemistry B</source> <volume>11</volume> (<year>2023</year>) <fpage>169</fpage>-<lpage>179</lpage>. <comment>https://doi.org/10.1039/D2TB01515C.</comment> <pub-id pub-id-type="doi">10.1039/D2TB01515C</pub-id></mixed-citation></ref>
<ref id="ref95"><label>[95]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pourhajibagher</surname><given-names>M.</given-names></name><name><surname>Bahador</surname><given-names>A.</given-names></name></person-group> <article-title>Virtual screening and computational simulation analysis of antimicrobial photodynamic therapy using propolis-benzofuran A to control of Monkeypox</article-title>. <source>Photodiagnosis and Photodynamic Therapy</source> <volume>41</volume> (<year>2023</year>) <fpage>103208</fpage>. <comment>https://doi.org/10.1016/j.pdpdt.2022.103208.</comment> <pub-id pub-id-type="doi">10.1016/j.pdpdt.2022.103208</pub-id></mixed-citation></ref>
<ref id="ref96"><label>[96]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alachouzos</surname><given-names>G.</given-names></name><name><surname>Schulte</surname><given-names>A.M.</given-names></name><name><surname>Mondal</surname><given-names>A.</given-names></name><name><surname>Szymanski</surname><given-names>W.</given-names></name><name><surname>Feringa</surname><given-names>B.L.</given-names></name></person-group> <article-title>Computational Design, Synthesis, and Photochemistry of Cy7&#x002D;PPG, an Efficient NIR&#x002D;Activated Photolabile Protecting Group for Therapeutic Applications</article-title>. <source>Angewandte Chemie</source> <volume>134</volume> (<year>2022</year>) <fpage>e202201308</fpage>. <comment>https://doi.org/10.1002/ange.202201308.</comment> <pub-id pub-id-type="doi">10.1002/ange.202201308</pub-id></mixed-citation></ref>
<ref id="ref97"><label>[97]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuzmina</surname><given-names>NS.</given-names></name><name><surname>Otvagin</surname><given-names>V.F.</given-names></name><name><surname>Maleev</surname><given-names>A.A.</given-names></name><name><surname>Urazaeva</surname><given-names>M.A.</given-names></name><name><surname>Nyuchev</surname><given-names>A.V.</given-names></name><name><surname>Ignatov</surname><given-names>S.K.</given-names></name><name><surname>Gavryushin</surname><given-names>A.E.</given-names></name><name><surname>Fedorov</surname><given-names>A.Y.</given-names></name></person-group> <article-title>Development of novel porphyrin/combretastatin A-4 conjugates for bimodal chemo and photodynamic therapy: Synthesis, photophysical and TDDFT computational studies</article-title>. <source>Journal of Photochemistry and Photobiology A: Chemistry</source> <volume>433</volume> (<year>2022</year>) <fpage>114138</fpage>. <comment>https://doi.org/10.1016/j.jphotochem.2022.114138.</comment> <pub-id pub-id-type="doi">10.1016/j.jphotochem.2022.114138</pub-id></mixed-citation></ref>
<ref id="ref98"><label>[98]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilic</surname><given-names>E.</given-names></name><name><surname>Elmazoglu</surname><given-names>Z.</given-names></name><name><surname>Almammadov</surname><given-names>T.</given-names></name><name><surname>Kepil</surname><given-names>D.</given-names></name><name><surname>Etienne</surname><given-names>T.</given-names></name><name><surname>Marion</surname><given-names>A.</given-names></name><name><surname>Gunbas</surname><given-names>G.</given-names></name><name><surname>Kolemen</surname><given-names>S.</given-names></name></person-group> <article-title>Activity-Based Photosensitizers with Optimized Triplet State Characteristics Toward Cancer Cell Selective and Image Guided Photodynamic Therapy</article-title>. <source>ACS Applied Bio Materials</source> <volume>5</volume> (<year>2022</year>) <fpage>2754</fpage>-<lpage>2767</lpage>. <comment>https://doi.org/10.1021/acsabm.2c00202.</comment> <pub-id pub-id-type="doi">10.1021/acsabm.2c00202</pub-id></mixed-citation></ref>
<ref id="ref99"><label>[99]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saedi</surname><given-names>A.</given-names></name><name><surname>Mashinchian Moradi</surname><given-names>A.</given-names></name><name><surname>Kimiagar</surname><given-names>S.</given-names></name><name><surname>Panahi</surname><given-names>H.A.</given-names></name></person-group> <article-title>Photosensitization of fucoxanthin-graphene complexes: A computational approach</article-title>. <source>Main Group Chemistry</source> <volume>21</volume> (<year>2022</year>) <fpage>1065</fpage>-<lpage>1075</lpage>. <comment>https://doi.org/10.3233/MGC-210188.</comment> <pub-id pub-id-type="doi">10.3233/MGC-210188</pub-id></mixed-citation></ref>
<ref id="ref100"><label>[100]</label> <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Lv</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Zu</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group> <article-title>New porphyrin photosensitizers&#x2014;Synthesis, singlet oxygen yield, photophysical properties and application in PDT</article-title>. <source>Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy</source> <volume>279</volume> (<year>2022</year>) <fpage>121447</fpage>. <comment>https://doi.org/10.1016/j.saa.2022.121447.</comment> <pub-id pub-id-type="doi">10.1016/j.saa.2022.121447</pub-id></mixed-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="fig001" position="float">
<label>Figure 1.</label>
<caption><p>Overview of the infection and theranostic approach against COVID-19.</p></caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ADMET-11-1883-g001.tif" mime-subtype="tif"/>
</fig>
<fig id="fig002" position="float">
<label>Figure 2.</label>
<caption><p>Nanoparticles used for prevention to treatment against SARS-CoV-2</p></caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ADMET-11-1883-g002.tif" mime-subtype="tif"/>
</fig>
<fig id="fig003" position="float">
<label>Figure 3.</label>
<caption><p>Schematic representation of the mechanism of PDT against viral infections</p></caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ADMET-11-1883-g003.tif" mime-subtype="tif"/>
</fig>
<table-wrap id="table001" position="float" orientation="portrait">
<label>Table 1.</label>
<caption><p>Summary of antiviral drugs being used for COVID-19 to suppress aggressiveness.</p></caption>
<table rules="all" frame="box">
<thead>
<tr>
<th align="center" valign="middle">No</th>
<th align="center" valign="middle">Name of the drugs</th>
<th align="center" valign="middle">Class of the drug</th>
<th align="center" valign="middle">Route of administration</th>
<th align="center" valign="middle">Mechanism of action</th>
<th align="center" valign="middle">Adverse effect</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="middle">1.</td>
<td align="center" valign="middle">Remdesivir</td>
<td align="center" valign="middle">Antiviral drug</td>
<td align="center" valign="middle">Intravenous (IV) injection</td>
<td align="center" valign="middle">Possess inhibitory activity by inhibiting viral RNA-dependent polymerase.</td>
<td align="center" valign="middle">Chest tightness, back pain, dark-colored urine, light-colored stools, flushing, headache, nausea, and vomiting.</td>
</tr>
<tr>
<td align="center" valign="middle">2.</td>
<td align="center" valign="middle">Dexamethasone</td>
<td align="center" valign="middle">Corticosteroid</td>
<td align="center" valign="middle">Oral / intravenous / intramuscular (IM) / intraarticular</td>
<td align="center" valign="middle">Inhibit a pro-inflammatory gene encoding cell adhesion molecules (CAM).</td>
<td align="center" valign="middle">Glaucoma, cataracts, fluid retention, hypertension, osteoporosis, mood swings, confusion, and irritation.</td>
</tr>
<tr>
<td align="center" valign="middle">3.</td>
<td align="center" valign="middle">Tocilizumab</td>
<td align="center" valign="middle">Antiviral drug</td>
<td align="center" valign="middle">IV infusion</td>
<td align="center" valign="middle">Binds to both sIL-6R and mIL-6R to inhibit the action.</td>
<td align="center" valign="middle">Stuffy nose, sore throat, headache, hypertension, and injection site reactions. The rare, more serious side effects include gastrointestinal perforations.</td>
</tr>
<tr>
<td align="center" valign="middle">4.</td>
<td align="center" valign="middle">Favipiravir</td>
<td align="center" valign="middle">Antiviral drug</td>
<td align="center" valign="middle">Oral</td>
<td align="center" valign="middle">inhibit replication of influenza A and B, Ebola, and other pathogenic viral infections, but the drug has shown promise in the treatment of avian influenza.</td>
<td align="center" valign="middle">Diarrhea, hyperuricemia, reduced neutrophil count, abdominal pain, nausea, and vomiting.</td>
</tr>
<tr>
<td align="center" valign="middle">5.</td>
<td align="center" valign="middle">Ivermectin</td>
<td align="center" valign="middle">Antiparasitic drug</td>
<td align="center" valign="middle">Subcutaneous / oral</td>
<td align="center" valign="middle">It targets the IMP&#x03B1; component and blocks the nuclear transport of viral proteins.</td>
<td align="center" valign="middle">Headache, dizziness, muscle pain, nausea, swollen lymph nodes, eye swelling, weakness, vision changes, and itching.</td>
</tr>
<tr>
<td align="center" valign="middle">6.</td>
<td align="center" valign="middle">Lopinavir /Ritonavir</td>
<td align="center" valign="middle">Antiretroviral</td>
<td align="center" valign="middle">Oral</td>
<td align="center" valign="middle">Inhibit the action of 3CL<sup>pro</sup> therapy to disrupt viral replication.</td>
<td align="center" valign="middle">Muscle weakness, diarrhea, heart burning, difficulty in sleep, muscle pain, nausea loss of appetite</td>
</tr>
<tr>
<td align="center" valign="middle">.7.</td>
<td align="center" valign="middle">Baricitinib</td>
<td align="center" valign="middle">Antirheumatic drug</td>
<td align="center" valign="middle">Oral</td>
<td align="center" valign="middle">Inhibit JAK1/JAK2 to modulate downstream inflammatory responses.</td>
<td align="center" valign="middle">Anemia, liver disease, nausea, loss of appetite, abdominal pain, yellowing eyes/skin, dark urine, fever, fainting.</td>
</tr>
<tr>
<td align="center" valign="middle">8.</td>
<td align="center" valign="middle">Chloroquine and hydroxychloroquine</td>
<td align="center" valign="middle">Antimalarial drug</td>
<td align="center" valign="middle">Subcutaneous / Intramuscular</td>
<td align="center" valign="middle">Inhibit endosomal acidification to block glycosylation and break down the production of viral proteins.</td>
<td align="center" valign="middle">Dizziness, loss of appetite, diarrhea, blurred vision, sensitivity to light, ringing in ears, muscle weakness, and mental change.</td>
</tr>
<tr>
<td align="center" valign="middle">9.</td>
<td align="center" valign="middle">Nafamostat and comostat</td>
<td align="center" valign="middle">Antiviral drug</td>
<td align="center" valign="middle">Ora l/ IV</td>
<td align="center" valign="middle">The antagonist of serine protease TMPRSS2 and inhibit SARS-CoV 2</td>
<td align="center" valign="middle">Rash, pruritus, nausea, abdominal discomfort, and liver enzyme level elevation</td>
</tr>
<tr>
<td align="center" valign="middle">10.</td>
<td align="center" valign="middle">Fluvoxamine</td>
<td align="center" valign="middle">Anti-inflammatory, antiviral, and antidepressant</td>
<td align="center" valign="middle">Oral</td>
<td align="center" valign="middle">Blocks reuptake of serotonin enhances its action</td>
<td align="center" valign="middle">Difficult breathing, skin rash, blisters, hives, fever, joint pain, swelling of the throat</td>
</tr>
<tr>
<td align="center" valign="middle">11.</td>
<td align="center" valign="middle">Umifenovir</td>
<td align="center" valign="middle">Antiviral</td>
<td align="center" valign="middle">Oral</td>
<td align="center" valign="middle">Inhibits membrane fusion of influenza virus and prevents contact between the virus and host tissues</td>
<td align="center" valign="middle">Nausea, vomiting, diarrhea</td>
</tr>
<tr>
<td align="center" valign="middle">12.</td>
<td align="center" valign="middle">Famotidine</td>
<td align="center" valign="middle">Histamine (H<sub>2</sub>) receptor antagonist</td>
<td align="center" valign="middle">Oral</td>
<td align="center" valign="middle">Activate the H<sub>2</sub> receptor and catalyze proton pump action to secrete acid</td>
<td align="center" valign="middle">Muscle cramps, abdominal discomfort, fatigue, anorexia, rash, dry mouth</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table002" position="float" orientation="portrait">
<label>Table 2.</label>
<caption><p>Recent findings on the effectiveness of PDT against viral infections</p></caption>
<table rules="all" frame="box">
<thead>
<tr>
<th align="center" valign="middle">No</th>
<th align="center" valign="middle">PS</th>
<th align="center" valign="middle">Wavelength, nm</th>
<th align="center" valign="middle">Target</th>
<th align="center" valign="middle">Finding</th>
<th align="center" valign="middle">Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="middle">1.</td>
<td align="center" valign="middle">5- Aminolevulinic Acid (5-ALA)</td>
<td align="center" valign="middle">635</td>
<td align="center" valign="middle">Juvenile laryngeal papilloma</td>
<td align="center" valign="middle">After PDT treatment, laryngeal papilloma was almost cured, and no recurrence was observed during 6-24 months of continuous physical assessment.</td>
<td align="center" valign="middle">PDT treatment with the combination of CO<sub>2</sub> laser therapy can be helpful for the common benign tumor, which can be related to human papillomavirus (HPV) infections.</td>
</tr>
<tr>
<td align="center" valign="middle">2.</td>
<td align="center" valign="middle">Curcumin</td>
<td align="center" valign="middle">450</td>
<td align="center" valign="middle">Pharyngo- tonsillitis</td>
<td align="center" valign="middle">PS was able to get delivered into the pharynx and tonsils. The microbial reduction in 1 log10 of the colony-forming unit was observed after therapy, and also recolonization was not observed after 24 h.</td>
<td align="center" valign="middle">The use of photodynamic therapy to treat Pharyngo- tonsillitis causes only minimal side effects.</td>
</tr>
<tr>
<td align="center" valign="middle">3.</td>
<td align="center" valign="middle">Methylene blue (MB)</td>
<td align="center" valign="middle">660</td>
<td align="center" valign="middle">Herpes simplex virus (HSV-1)</td>
<td align="center" valign="middle">After PDT, the first session showed betterment in anti-inflammatory activity and itching and increased the healing process of wounds.</td>
<td align="center" valign="middle">Treating herpes simplex infections in the nasal wing with PDT and photobiomodulation was beneficial and delivering drug (PS) via nebulization can overcome drug release problems, minimizing side effects caused due to IV administration.</td>
</tr>
<tr>
<td align="center" valign="middle">4.</td>
<td align="center" valign="middle">Methylene blue (MB) and Radahlorin</td>
<td align="center" valign="middle">662</td>
<td align="center" valign="middle">Vero E6 cells and SARS- CoV 2</td>
<td align="center" valign="middle">In the presence of MB and Radahlorin, the <italic>IC</italic><sub>50</sub> of 10<sup>2</sup> TCID<sub>50</sub> of SARS CoV-2 was found as 0.22 &#x03BC;g/ml and 0.33 &#x03BC;g/ml. Inhibitory concentration-50% for Radahlorin and MB was observed at 0.6 &#x03BC;g/ml and 2 &#x03BC;g/ml.</td>
<td align="center" valign="middle"><italic>In vitro</italic>, when PDT is coupled with Radahlorin and MB, high antiviral efficacy against SARS-CoV-2 was observed.</td>
</tr>
<tr>
<td align="center" valign="middle">5.</td>
<td align="center" valign="middle">Phenothiazines, Methylene blue (MB), Porphyrins, Protoporhphyrine-IX (PP-IX)</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">COVID- 19</td>
<td align="center" valign="middle">aPDT treatment using cost-effective PS could assist in mitigating COVID-19 by treating infected individuals by developing functional photoactive textiles, auto-disinfecting surfaces, and disinfecting water and air.</td>
<td align="center" valign="middle">Photosensitizers MB and PP-IX are new technical methods to treat COVID-affected patients in a less costly and safer way by disinfecting infected water and water surface which cause the COVID disease.</td>
</tr>
<tr>
<td align="center" valign="middle">6.</td>
<td align="center" valign="middle">Methylene blue</td>
<td align="center" valign="middle">660</td>
<td align="center" valign="middle">Lip lesions</td>
<td align="center" valign="middle">0.1 % methylene blue (MB) photosensitizer was applied all over lip lesions and treated with aPDT and photomodulation showed complete healing in 4 days.</td>
<td align="center" valign="middle">COVID-19-related labial lesions can be efficiently treated by combining phototherapy modalities.</td>
</tr>
<tr>
<td align="center" valign="middle">7.</td>
<td align="center" valign="middle">Curcumin poly-lactic-co- glycolide acid</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">SARS-CoV-2, Vero cells</td>
<td align="center" valign="middle">aPDT had anti-COVID action <italic>in vitro</italic> without causing Cytotoxicity in Vero cells cultured with SARS-CoV-2 treated plasma</td>
<td align="center" valign="middle"><italic>In vitro</italic>, COVID-19 action was observed in treated plasma containing SARS-CoV- 2 without apoptosis in Vero cell or any negative effect on plasma quality in photodynamic therapy.</td>
</tr>
<tr>
<td align="center" valign="middle">8.</td>
<td align="center" valign="middle">5- aminolevulinic acid</td>
<td align="center" valign="middle">635</td>
<td align="center" valign="middle">HSIL (high-grade intraepithelial lesion)/CIN2 (cervical squamous intraepithelial neoplasia 2) with high-risk Human Papillomavirus (hHPv)</td>
<td align="center" valign="middle">5-ALA PDT possessed higher safety and efficacy profile for the HSIL/CIN2 patients needing reproductive treatment. It can be a promising alternative surgical technique.</td>
<td align="center" valign="middle">ALA-PDT is effective for treating cervical HSIL and high-risk HPV infections, and the effect may be maintained for a long time.</td>
</tr>
<tr>
<td align="center" valign="middle">9.</td>
<td align="center" valign="middle">Porphyrin</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">SARS-CoV-2</td>
<td align="center" valign="middle">Coating of siloxane copolymer onto the textiles produces excitation of porphyrin that shows <sup>1</sup>O<sub>2</sub> oxidative crosslinking of the polysiloxane with amine links to create hydrophobic fabric.</td>
<td align="center" valign="middle">The development of a treated mask can be a barrier and provide better inactivation of viral structures for the transmission of SARS-CoV-2 and also have broad-antiviral activity application against human-enveloped viruses such as influenza A virus and other coronaviruses.</td>
</tr>
<tr>
<td align="center" valign="middle">10.</td>
<td align="center" valign="middle">Methylene blue</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">Influenza virus, SARS-CoV- 2, and MERS (Middle East Respiratory Syndrome)</td>
<td align="center" valign="middle">As studies suggest, MB-mediated aPDT can minimize COVID-19 impact in the absence of therapy for COVID-19.</td>
<td align="center" valign="middle">Methylene Blue as PS for aPDT can take control of coronavirus and helps to eradicate it. More research is required for the use of antiviral PDT as a treatment against COVID-19.</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table003" position="float" orientation="portrait">
<label>Table 3.</label>
<caption><p>Nanoenabled immunization against COVID-19</p></caption>
<table rules="all" frame="box">
<thead>
<tr>
<th align="center" valign="middle">No.</th>
<th align="center" valign="middle" colspan="2">Vaccine</th>
<th align="center" valign="middle">Vaccine type</th>
<th align="center" valign="middle">Administration regimen</th>
<th align="center" valign="middle">Target virus</th>
<th align="center" valign="middle">Target Disease</th>
<th align="center" valign="middle">Nanoformulation</th>
<th align="center" valign="middle">Mode of action</th>
<th align="center" valign="middle">Company</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="middle" rowspan="5">1.</td>
<td align="center" valign="middle" rowspan="5">BNT162</td>
<td align="center" valign="middle">BNT162a1</td>
<td align="center" valign="middle">Uridine mRNA (uRNA) vaccine</td>
<td align="center" valign="middle">Prime/Boost (P/B) regimen</td>
<td align="center" valign="middle" rowspan="5">SARS-CoV-2</td>
<td align="center" valign="middle" rowspan="5">Covid-19</td>
<td align="center" valign="middle" rowspan="5">Lipid Nanoparticles (LNP)</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle" rowspan="5">BioNTech and Pfizer</td>
</tr>
<tr>
<td align="center" valign="middle">BNT162b1</td>
<td align="center" valign="middle">Nucleoside-modified RNA vaccine</td>
<td align="center" valign="middle">P/B regimen</td>
<td align="center" valign="middle">Targets the spike protein of membrane-bound SARS-CoV-2 and encodes for its prefusion state.</td>
</tr>
<tr>
<td align="center" valign="middle">BNT162b2 or Comirnaty</td>
<td align="center" valign="middle">Nucleoside-modified RNA vaccine</td>
<td align="center" valign="middle">P/B regimen</td>
<td align="center" valign="middle">Targets the spike protein of SARS-CoV-2 and encodes their receptor-binding domain, thereby eliciting human antibody and T<sub>H</sub>1 T cell responses</td>
</tr>
<tr>
<td align="center" valign="middle">BNT162b3</td>
<td align="center" valign="middle">Nucleoside-modified RNA vaccine</td>
<td align="center" valign="middle">P/B regimen</td>
<td align="center" valign="middle">NA</td>
</tr>
<tr>
<td align="center" valign="middle">BNT162c2</td>
<td align="center" valign="middle">Self-amplifying mRNA (saRNA) vaccine</td>
<td align="center" valign="middle">P/B regimen or Single dose (SD) regimen</td>
<td align="center" valign="middle">NA</td>
</tr>
<tr>
<td align="center" valign="middle">2.</td>
<td align="center" valign="middle" colspan="2">LUNAR-COV19</td>
<td align="center" valign="middle">Self-transcribing and replicating mRNA vaccine</td>
<td align="center" valign="middle">P/B regimen or SD regimen</td>
<td align="center" valign="middle">SARS-CoV-2</td>
<td align="center" valign="middle">Covid-19</td>
<td align="center" valign="middle">LNP</td>
<td align="center" valign="middle">Encodes the SARS-CoV-2 spike protein and an alphavirus-based replicon.</td>
<td align="center" valign="middle">Arcturus therapeutics</td>
</tr>
<tr>
<td align="center" valign="middle">3.</td>
<td align="center" valign="middle" colspan="2">Spikevax or mRNA-1273 or elasomeran</td>
<td align="center" valign="middle">Nucleoside-modified RNA vaccine</td>
<td align="center" valign="middle">Two dose (TD) regimen</td>
<td align="center" valign="middle">SARS-CoV-2</td>
<td align="center" valign="middle">Covid-19</td>
<td align="center" valign="middle">LNP</td>
<td align="center" valign="middle">Targets the spike glycoprotein of SARS-CoV-2 and encodes for its prefusion state.</td>
<td align="center" valign="middle">Moderna</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table004" position="float" orientation="portrait">
<label>Table 4.</label>
<caption><p>The summary of the computer-aided designing and analysis of PS.</p></caption>
<table rules="all" frame="box">
<thead>
<tr>
<th align="center" valign="middle">No</th>
<th align="center" valign="middle">PS designed</th>
<th align="center" valign="middle">Method used</th>
<th align="center" valign="middle">Purpose</th>
<th align="center" valign="middle">Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="middle">1.</td>
<td align="center" valign="middle">Palladium-Platinum complex</td>
<td align="center" valign="middle">Gaussian 16 program</td>
<td align="center" valign="middle">Two-photon PDT cancer therapy</td>
<td align="center" valign="middle">[<xref ref-type="bibr" rid="ref91">91</xref>]</td>
</tr>
<tr>
<td align="center" valign="middle">2.</td>
<td align="center" valign="middle">Imidazolium-based porous organic polymer photosensitizer</td>
<td align="center" valign="middle">Non-adiabatic molecular dynamics simulation</td>
<td align="center" valign="middle">Anticancer PDT</td>
<td align="center" valign="middle">[<xref ref-type="bibr" rid="ref92">92</xref>]</td>
</tr>
<tr>
<td align="center" valign="middle">3.</td>
<td align="center" valign="middle">Benzothiazole-based organic PS</td>
<td align="center" valign="middle">Gaussian 16 program</td>
<td align="center" valign="middle">Novel design of organic PS that is operative in the NIR region</td>
<td align="center" valign="middle">[<xref ref-type="bibr" rid="ref93">93</xref>]</td>
</tr>
<tr>
<td align="center" valign="middle">4.</td>
<td align="center" valign="middle">Halogen-free boron dipyrromethene photosensitizer</td>
<td align="center" valign="middle">Density Functional Theory (DFT) with the dependence on time (TDDFT)</td>
<td align="center" valign="middle">Bioimaging and anticancer PDT</td>
<td align="center" valign="middle">[<xref ref-type="bibr" rid="ref94">94</xref>]</td>
</tr>
<tr>
<td align="center" valign="middle">5.</td>
<td align="center" valign="middle">Propolis-benzofuran A photosensitizer</td>
<td align="center" valign="middle">SwissADME tool, OSIRIS and Pro-Tox II</td>
<td align="center" valign="middle">PDT for Monkeypox virus</td>
<td align="center" valign="middle">[<xref ref-type="bibr" rid="ref95">95</xref>]</td>
</tr>
<tr>
<td align="center" valign="middle">6.</td>
<td align="center" valign="middle">Cy7- Photolabile Protecting Groups</td>
<td align="center" valign="middle">GaussView 6.0</td>
<td align="center" valign="middle">Facile synthesis for biomedical applications</td>
<td align="center" valign="middle">[<xref ref-type="bibr" rid="ref96">96</xref>]</td>
</tr>
<tr>
<td align="center" valign="middle">7.</td>
<td align="center" valign="middle"><italic>Meso</italic>-tetraphenylporphyrin</td>
<td align="center" valign="middle">TDDFT</td>
<td align="center" valign="middle">Anticancer PDT</td>
<td align="center" valign="middle">[<xref ref-type="bibr" rid="ref97">97</xref>]</td>
</tr>
<tr>
<td align="center" valign="middle">8.</td>
<td align="center" valign="middle">Dicyanomethylene-4H-chromene based PS</td>
<td align="center" valign="middle">Mesra software with Gaussian 16 program</td>
<td align="center" valign="middle">Image-guided anticancer PDT</td>
<td align="center" valign="middle">[<xref ref-type="bibr" rid="ref98">98</xref>]</td>
</tr>
<tr>
<td align="center" valign="middle">9.</td>
<td align="center" valign="middle">Fucoxanthin/graphene complex</td>
<td align="center" valign="middle">DFT</td>
<td align="center" valign="middle">To study the photosensitization features for various applications</td>
<td align="center" valign="middle">[<xref ref-type="bibr" rid="ref99">99</xref>]</td>
</tr>
<tr>
<td align="center" valign="middle">10.</td>
<td align="center" valign="middle">Porphyrin-based PS with two ethanethioate</td>
<td align="center" valign="middle">DFT and TDDFT</td>
<td align="center" valign="middle">Calculation of the excited state properties of the novel design</td>
<td align="center" valign="middle">[<xref ref-type="bibr" rid="ref100">100</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>